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ABSTRACT
The objective of the project is to develop a 3D printed scaffold capable of permitting quick
release of the anti-inflammatory Dexamethasone, while simultaneously maintaining slow
release of the anti-epileptic drug Phenytoin. It is anticipated that the scaffold will be suitable
for intracerebral implantation for the prophylactic treatment of seizures: the slow release
anti-epileptic intended as a replacement for daily self-medication, and the simultaneous
short-term release of the anti-inflammatory in order to minimise any inflammation caused
during implantation. The implant serves not only for the prophylactic treatment of epilepsy
patients, but also presents a use in the prophylactic treatment of seizures in patients who are
at high risk of postoperative seizures when implanted following a neurosurgical procedure.
Unlike traditional drug release models, which generally are restricted to a single drug, this
research involves multi-drug release; utilizing advances in the field of 3D Bioprinting. New
breakthroughs in 3D bioprinting allow fabrication of composite multi-polymer structures that
permit the complex release profiles required for multi-drug delivery systems.
The project explores the extrusion printing of drug-loaded scaffolds with analysis into the
effect of polymer type, synthesis and variation in 3D structures on the drug-release profile. It
then focuses on the fabrication of a 3D structured polymer composite, enabling the
concurrent dual release of the quick-release Dexamethasone and the slow release Phenytoin;
altering release rates initially via the simple variation of scaffold morphology such as layer
number, and then moving onto more complex variations such as shell shape and thickness.
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ABBREVIATIONS
ACN

Acetonitrile

AED

Anti-epileptic drug

CT

Computed Tomography

DDS

Drug Delivery System

DDM

Drug Delivery Modification

DEX

Dexamethasone

EEG

Electroencephalogram

FDA

Federal Drugs Administration

FDM

Fused Deposition Modelling

FTIR

Fourier Transform Infrared Spectroscopy

HPLC

High Pressure Liquid Chromatography

ILAE

International League Against Epilepsy

IPRI

Intelligent Polymer Research Insitute

NMR

Nuclear Magnetic Resonance

MRI

Magnetic Resonance Imaging

PBS

Phosphate Buffered Saline

PCL

Polycaprolactone

4

PDLLA

Poly(DL-lactide)

PECA

poly(ethylcyanoacrylate)

PEG

Poly (ethylene glycol)

PGA

Poly(glycolic acid)/Polyglycolide

PHT

Phenytoin

PLGA

Poly(lactic-co-glycolic acid)

UV-Vis

Ultraviolet-Visible
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1. INTRODUCTION AND LITERATURE REVIEW
1.1 EPILEPSY
Epilepsies cover a range of brain syndromes from comparatively benign, to severe and life
threatening. In epilepsy, the normal pattern of neural activity is disrupted, causing a number
of symptomatic responses: behavioural, such as bizarre sensations and emotions; and
physical including convulsions, muscle spasms, and loss of consciousness. The epilepsies have
multiple causes and there are several types of seizures. Any deviation from the normal
pattern of neuronal activity—from disease to physical trauma to abnormal brain
development—can lead to seizures. Epilepsy may develop because of an aberration in neural
wiring, an imbalance of neurotransmitters, and many other factors. The occurrence of a single
seizure as a consequence of high fever (called febrile seizure) or head injury does not
necessarily indicate that a patient has epilepsy. Only when a patient has had two or more
seizures may he or she be considered to have epilepsy (Fisher et al., 2014). Analysis of neural
activity using Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) is the most
common diagnostic test for epilepsy (Takanashi, 2014). Fig. 1 demonstrates the variance in

A

B

C
Figure 1: EEG of epilepsy-free patients (A) and epileptic patients before (B) and during (C) seizure (Ebrahimpour,
Babakhani, Arani, & Masoudnia, 2012)

electrical activity in the brain for those that suffer from epilepsy (Fig.1 B & C) and those
without (Fig. 1 A). Fig. 1 C demonstrates the excessive firing of neurons during epilepsies. The
high electroencalographic discharge can be useful in localising the source of the seizure.
The definition of epilepsy has been updated and amended over the years from a concise
1973 definition: a chronic brain disorder of various aetiologies characterized by recurrent
12

seizures due to excessive discharges of cerebral neurons, associated with a variety of clinical
and laboratory manifestations (Gastaut, 1973) to the slightly more verbose present definition
by the International League Against Epilepsy (ILAE): a disease of the brain defined by any of
the following conditions: (1) At least two unprovoked (or reflex) seizures occurring >24 h
apart; (2) one unprovoked (or reflex) seizure and a probability of further seizures similar to
the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the
next 10 years; (3) diagnosis of an epilepsy syndrome (Fisher et al., 2014).
Over 10% of the population are at risk of experiencing a seizure during their lifetime, and
3-4% will be diagnosed with epilepsy (Hauser, Annegers, & Rocca, 1996). Although originally
believed to be a disorder of youth, the over 55 age group is now considered to be the most
vulnerable population (Forsgren, Beghi, Oun, Sillanpää, & Umeå universitet, 2005).
1.1.1

Seizure classification

As with definitions, the classification of seizures has developed over the decades, but
presently there is no clear agreement on what the defining areas of classification should be,
and how to merge them into a coherent summary. Options include: seizure type, syndrome
type, aetiology, semiology, and age at onset. Many proposals have been put forward however
there are concerns that any changes in classification and terminology will result in a)
obfuscation for (the general medical community b) the necessity to revise regulations and
guidelines in the non-medical field c) no benefit to research. The current trend is to consider
each of these ‘areas’ or ‘parameters’ separately.
Aetiological classification (causation)


Idiopathic epilepsy



Symptomatic: genetic or developmental



Symptomatic: acquired

Seizure type classification


Localisation related (focal, local and partial)



Generalised



Undetermined e.g. neonatal seizures that exhibit both local and general
13



Special syndromes (situation-related seizures such as febrile convulsions)

Status epilepticus is a type of seizure that has received its own definition and classification
in recent decades: Status epilepticus (SE) is a condition in which epileptic activity persists for
30 minutes or more, causing a wide spectrum of clinical symptoms, and with a highly variable
pathophysiological, anatomical and aetiological basis (S. Shorvon, 2001).
1.1.2

Treatment

There are a variety of treatment options for epilepsy which include, but are not limited to,
medication, diet, surgery (focal resection, hemispherectomies and corpus callosotomies) and
vagus nerve stimulation. Medication choice is dependent on a variety of factors including age,
co-medications, seizure syndrome, and frequency of seizures. Diet, in particular the ketogenic
diet which involves strict compliance, precise food measurements and a hospital stay; and
the modified Atkins diet, have been shown to lower seizure rates. In cases where neither of
the above is suitable, surgery is an option with a number of viable choices depending on the
case. Focal resection involves the removal of the portion of the brain where seizures originate
but is only effective for consistent local seizures. A hemispherectomy is suitable for very few
patients, as it involves almost the complete removal of a hemisphere of the brain. A corpus
callosotomy, on the other hand, interrupts the seizure pathway and confines the seizure to a
small part of the brain. Vagus nerve stimulation is invasive, but not to the extent of full brain
surgery, and uses a pacemaker like device to stimulate the vagus nerve, thereby increasing
cortiex inhibition and, consequently, reducing the likelihood of seizures (Treatment | Epilepsy
Society," 2015).
1.1.3

Development of anti-epileptic drugs

Drug therapy for epilepsy has expanded greatly since the end of the 1950’s. There were
two key periods of drug development: pre-1989, in which carbamazepine, valproate and the
benzodiazepines were created, and post-1989, where lamotrigine, oxcarbazepine and
leviteracetam emerged. These days over 29 different drugs/drug therapies are used in the
treatment of epilepsy. Research doesn’t operate in a vacuum and over the decades, large
progress was made in other fields which influenced and aided in the development of antiepileptic drugs.
14

The field of pharmacokinetics greatly expanded during the 60’s and early 70’s, in which the
principles of absorption, metabolism, excretion and drug-drug interaction were described.
The introduction of Carbamazepine and Valproate, in conjunction with the rise in clinical
pharmacokinetics, resulted in an increase in epilepsy as a subject. This increased further with
the introduction of diagnostic aids such as the Electroencephalogram (EEG) and
neuroimaging.
Pre 1950s, there was very little drug legislation with only the Food, Drug and Cosmetic Act
being passed in 1938 in the U.S., which required evidence of safety to be submitted before
marketing (Lennox & Lennox-Buchthal, 1960). Following the Thalidomide debacle of the late
50s and early 60s, the Kefauver Harris Amendment was passed in the US which required
stringent evaluation of efficacy and safety of medicines before going on market as well as
continuous evaluation of those drugs already on the shelves. Further amendments also
required drug advertising to disclose specific safety information. Unlike with
pharmacokinetics, this had negative consequences on anti-epileptic drug research. The cost
of drug development increased dramatically as did the complexity of testing. In 1972, the ILAE
Commission on Antiepileptic Drugs and the Federal Drugs Administration (FDA) created a
document, subsequently adopted globally, outlining the correct procedure for conducting
drug trials, including patient selection and protocols (Penry, 1973). It is still in use today
globally.
Prior to the late 1970s, combination therapy was considered the norm for the treatment
of epilepsy. However, with the introduction of a wider range of effective drugs e.g.
carbamazepine and an increase in the quality of anti-epileptic drug trials, the emphasis moved
to monotherapy. In the late 1980s, regulations were passed which required monotherapy
trials for any drug that was to be used independently. (Simon D. Shorvon, 2009).
1.1.4

Modern drug treatment

Today there are over 29 different antiseizure medications available, some of which had
been developed many decades ago and others which have only recently come onto the
market (S. D. Shorvon, Perucca, & Engel, 2016). While this can be considered a blessing in that
the choice of drug can be accurately tailored to the patient, drug selection is now a much
more complicated process involving the familiarisation of dosages, contraindications and
15

properties. Factors to be considered in choosing an antiepileptic drug fall into two sections:
medication related and patient related. Medication related includes efficacy, frequency of
administration, side effects and even more practical considerations such as cost. Patient
related, on the other hand, includes factors such as age and gender, seizure type and
syndrome, risk factors and co-medications.
1.1.5

Present challenges

Once a drug is chosen, there are still a variety of issues that must be addressed. In the short
term, regular monitoring to test efficacy of drug (pharmacokinetics) and possible side effects
must be considered. Longer term considerations include patient compliance and the altering
of treatments. The use of a drug-loaded cerebral implant is a viable option for the
minimisation/removal of some of the aforementioned issues, in particular patient compliance
(removal of daily administration) and drug efficacy (bypassing of traditional drug
administration pathways and minimisation of interaction with other drugs).
1.1.5.1 Phenytoin and Drug Pharmacology
Phenytoin is an anti-convulsant (anti-epileptic) that is used in a wide variety of seizure
indications. Phenytoin comes in two forms: the base drug, and Fosphenytoin, a water-soluble
prodrug. It has been marketed since the early 50s and while administration is usually oral, it
can also be administered intravenously and intramuscularly. Phenytoin is a hydantoin, which
at therapeutic concentrations blocks repetitive firing of neurons and maintains sodium ion
channels, thus minimizing risk of seizure. It is primarily used for prophylactic management of
tonic-clonic (grand mal) and partial seizures and is often used during and after neurosurgery
to prevent/treat seizures. Due to slow onset, in order to treat status epilepticus, it is usually
preceded by two doses of benzodiazepam.
Phenytoin has a high bioavailability when taken orally (70-100%), but considerably lower
when administered intravenously or rectally (24%) with peak blood concentration expected
between 3-12 hours. The half-life of Phenytoin is 12-36 h and steady state concentration is
reached after 7 days. Metabolism is primarily hepatic and is catalysed via CYP2C19/CYC2C9
enzymes. A majority of the drug is excreted in bile as inactive metabolites, reabsorbed in the
intestine and excreted via urine (McEvoy Gk, 2004). It has a narrow therapeutic range (10-20
µg/ml-total serum concentration), and there have been reports of intoxication and decreased
16

effectiveness. There are many reports of drugs increasing and decreasing the metabolism of
Phenytoin, including, importantly, Dexamethasone. (Nation, Evans, & Milne, 1990)
1.1.6

Inflammation associated with neurosurgery/implantation

Cerebral oedema complicates many neurosurgical conditions and is a direct result of
operative trauma. This can lead to other conditions such as brain herniation and intercranial
hypertension. Corticosteroids have often been used peri-operatively to prevent postoperative oedema, of which Dexamethasone is most commonly used due to the high antiinflammatory activity, lack of mineralocorticoid activity and long half-life (Weber & Griffin,
1994). In addition, the implantation of artificial organs, medical devices or biomaterials can
result in inflammation; the form it takes is dependent on form and topography of the
implanted device (Alessandro, Wágner José, Paulo, & Cássio Luis Zanettini, 2016). Given the
desire in this project to produce a cerebral implant for the prophylactic treatment of epilepsy,
it seems apt to include an anti-inflammatory within the implant to prevent the likely
inflammation of surrounding tissue during implantation.
1.1.7

Post-operative seizures

A dual anti-inflammatory/anti-epileptic implant serves not only for the prophylactic
treatment of epilepsy patients, but also presents a use in the prophylactic treatment of
seizures in patients who are at high risk of postoperative seizures. A study into the use of
Leviteracetam as a prophylactic anti-epileptic drug in the immediate post-operative period
(Gokhale, Khan, Agrawal, Friedman, & McDonagh, 2013) found that use of the drug greatly
reduced the incidence of post-operative seizure.
1.1.8

Dexamethasone and Drug Pharmacology

Dexamethasone is a corticosteroid that prevents the release of substances in the body that
cause inflammation. It is used to treat many different inflammatory conditions such as allergic
disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders.
Dexamethasone is available in three main forms: base Dexamethasone, Dexamethasone
Sodium Phosphate, and Dexamethasone Acetate. For this project the base drug will be
employed. Dexamethasone, in all its forms, has been manufactured for a number of decades,
and is administered via several routes, including oral, ophthalmic, intramuscular, intravenous
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and intrasynovial. Dexamethasone has high bioavailability (80-90%) when taken orally with
peak plasma concentrations after one hour. Metabolism is hepatic, and is catalysed via the
CYP3A4 enzyme, and it has a broad therapeutic index. When taken concurrently with
Phenytoin, there is an increase in metabolic clearance rate and reduction in plasma half-life
by up to 50% due to induction of liver enzyme CYP3A4 by Phenytoin. (Dietrich, Rao, Pastorino,
& Kesari, 2011)
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1.2 DRUG DELIVERY SYSTEMS
1.2.1

History of drug delivery system modification

The first attempts at Drug Delivery Modification (DDM) involved the coating of pills to mask
the undesirable taste of drugs. First advances occurred in the 1940’s, in which DDM was used
to release a primary dose of active agent in the stomach and a secondary dose in the intestine.
These were sensitive to physiological variables.
The following twenty years were focused on sustained/prolonged release, using primarily
hydrophobic polymers and waxes. As little was known about physiological and anatomic
barriers of organisms, development of new systems was difficult. Early successes included the
Spansule®, a time release capsule loaded with the anti-depressant Dexedrine (Smith, 1955),
and Contact®, a cold medicine. Additionally, biodegradable polymers such as Polyglycolide
(PGA), Polylactic Acid (PLA) and poly(lactic-co-glycolic acid) (PLGA) were synthesised and
patented (Schmitt, 1967). Near the end of the 1960’s, research was being conducted into the
concept of controlled drug delivery. These developments would not be put into practice until
the next decade.
The 1970’s and 1980’s brought on a greater understanding of aetiology and the concept
of therapeutic systems, and this had a great effect on DDM, from macroscopic zero-order
devices in the 70s and early 80s, to microscopic biodegradable sustained release systems in
the late 1980s (Hoffman, 2008). Exploiting the polymer research from earlier decades,
polymer-drug conjugates were created including a contraceptive medication consisting of a
contraceptive steroid coated in polymer. Decapeptyl, a hormone therapy drug, was clinically
approved in the early 80s, unique in that it was the first injectable, degradable microparticle
drug delivery system (DDS) to be approved. Also in development were liposomes and
micelles, which brought us into the 90s, the ‘modern’ age of drug delivery.
The start of the 1990’s brought with it work on nucleic acid drugs which has led to the
development of condensed plasmid DNA (pDNA) nanoparticles. As time progressed, a slew of
new systems was created and put into clinical use including mucoadhesive DDS (using
Chitosan and cellulose derivatives), nanoscale albumin-based drug carriers, liposomal
formulations and dendrimers. This period of DDM research was informed by a growing
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understanding of DNA sequencing, specifically in relation to diseases, which has allowed for
the precise tailoring of therapeutic regimes for optimal treatment. (Bruschi, 2015)

1.3 POLYMER DRUG RELEASE
1.3.1

Basics of drug release

Biopharmacy studies the physiological and pharmaceutical factors influencing drug
release. These factors fall under three main sections: administration, release, and absorption.
Drugs can enter the body via a variety of different routes including, but not limited to:
parenterally, enteric, and topical. Each route of administration has its advantages and
disadvantages, and often drug choice is dependent on the form of administration. The form
of administration is chosen based on age of patient, illness, and a variety of other factors. This
in turn affects the rate of absorption into the body. Oral administration, for example, will
necessitate absorption via the stomach in which pH is a determining factor in the release rate
of the drug. There are a variety of drug release systems which have been devised over the
years e.g. matrix tablets, implants, capsules, and suspensions, and each system will create a
unique release profile in a lab setting. The variation in their structure and composition can be
as much a determining factor in establishing a release profile as external factors such as pH
(Bruschi, 2015).
1.3.2

Drug Release Profiles & Serum concentration

The release of a drug from a system can follow a number of different profiles (Figure 2),
which include burst, zero order, first order, and pulsatile release. Burst release describes the
initial drug release upon placement in medium e.g. Panadol® (Paracetamol) capsules with
Optizorb® technology which allows for release within 7 minutes. Zero order release
describes release at a constant rate, independent of concentration of reactants e.g.
Duragesic® transdermal patch (Opioid). First order release describes release with a constant
change in release rate, proportional to concentration of reactants e.g. Nurofen® back pain
sustained-release capsules (ibuprofen). Pulsatile release is periodic release with goal being
to keep the drug concentration within the therapeutic range for the longest possible time
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e.g. Naprelan® (NSAID) which uses IPDAS® technology to provide pain relief within 30
minutes, lasting 24 hours (Garg, Bilandi, Kapoor, Kumar, & Chanana, 2011).
Effect of release kinetics on serum concentration
Toxic
Serum Concentration

Zero-order release
Therapeutic

Pulsatile release

First order
Subtherapeutic

Burst release

Time
Figure 2: Diagram of the effect of release kinetics on serum concentration

Each of these release profiles correlates to a different concentration of drug in the serum
(disregarding other factors affecting absorption). Serum concentration is the determining
factor in whether the drug dosage is correct. Too low a serum concentration, the effects of
drug are weakened. Too high a concentration, and the likelihood of toxicity is increased
(Burton, 2006). The band of acceptable concentrations is known as the therapeutic window
(Fig. 2). The therapeutic index is defined as the ratio of upper (toxic) and lower (effective)
levels, i.e.
ℎ
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(

)]
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For some drugs, such as the analgesic Remifentanil, the index is extremely forgiving
(33,000:1), whereas other drugs, such as the anti-epileptic Phenytoin, require extremely
precise dosages due to their narrow windows (2:1). For cases in which there is a large
therapeutic index, a variety of options are available for drug release. However, for drugs such
as Phenytoin, a zero-order release is preferable. Notably, the majority of drug release systems
feature burst release, and in this case, it is important to try and minimise this burst release as
it may cause toxicity issues in the patient.
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1.3.3

Biodegradable polymers for Drug Release

The polymer type is the defining factor in determining the shape of the release profile.
Shape and size of the system may affect the comparative rate of release, but it is the polymer
choice which sets the ‘order’ of release. Before designing a drug release system for in body
use, there are two requirements that must be satisfied. Firstly, the polymer must be
biodegradable for in-vivo use, with the resultant products being non-biohazardous and able
to be metabolised by the body. Biodegradability is a necessity in order to avoid extraction
once the drug has been depleted. Secondly, the drug-release polymer properties must be
reproducible. Although there is a plethora of natural biodegradable polymers, the majority
are unable to be used in drug delivery systems due to their batch to batch variability and
immunogenicity. As such, synthetic polymers are most commonly used (Bruschi, 2015).
Polymer types used in drug release include polyesters, poly-anhydrides and polyamides.
The most common polymers are Poly(lactic-co-glycolic acid) (PLGA), Polylactic Acid (PLA) and
Polycaprolactone (PCL). Material properties such as hydrophobicity, molecular weight, glass
transition temperature and crystallinity can all affect the drug release, which generally occurs
via either surface erosion, polymer chain cleavage on surface/in bulk, or via diffusion of the
drug through the polymer.
These polymer properties can also affect the ability to fabricate DDS. For example, the use
of a FDM (Fused Deposition Modelling) printer in producing scaffolds is only possible with low
molecular weight polymers, due to difficulty in extrusion, as the greater the molecular weight
the higher the viscosity. For example, a polymer with M.W. of 192,000 g/mol will have 41%
of the viscosity of the same polymer with M.W. of 250,000 g/mol (Locati & Gargani, 2018).
1.3.4

Development and optimisation of Biodegradable polymers for drug delivery

1.3.4.1 PCL
Given the amicable nature (non-cytotoxic and biodegradable) and tailorable properties of
PCL, it has been trialled in almost all novel DDSs and tissue engineering systems in recent
times (Dash & Konkimalla, 2012). It can be easily copolymerised and/or blended and is
compatible with natural polymers such as chitosan and minerals such as Hydroxyapatite (HA).
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Many formulations of PCL have been created including microspheres, nanoparticles,
scaffolds, films, fibres and hydrogels.
Microspheres

are

free

flowing

particles

of

size

50

µm-2

mm,

and

the

entrapped/encapsulated drug is released by erosion (matrix) and diffusion (matrix and
reservoir). Preparation of microspheres is dependent on choice of drugs, and release kinetics
are dependent on preparation, processing and polymer composition (Varde & Pack, 2004).
Different forms

of solvent evaporation

methods

allow for evaporation

of

hydrophilic/lipophilic drugs, but all have the distinct disadvantage in that there are often
residual solvents in the final product. An alternative to this is the use of spray drying/hot melt
extrusion for thermostable drugs. Lipophilic drugs are dispersed evenly within the spheres
whereas hydrophilic drugs are localised near the surface (J. Lee, Oh, Joo, & Jeong, 2008).
Nanoparticles, in contrast to microspheres, are sub-micron spheres. As with microspheres,
its properties are dependent on polymer composition and organic solvent used. They are
unique amongst drug delivery formulations due to their size, customizability of surface and
drug release properties, high solubility, and drug stabilisation.
Scaffolds are porous structures mainly used for tissue engineering. PCL scaffolds are
preferably used in 3D cell culture. There is a plethora of methods for scaffold fabrication
ranging from common electrospinning and extrusion, to the newer FDM and melt spinning
methods. Regarding drug release, variation of ratios in PCL blends and composites e.g. PCLChitosan has been shown to have large effects on swelling, surface homogeneity and total
release (S. Sahoo, 2010).
Fibres are preferable when the intended release is sustained and without burst release.
Methods include electrospinning, gravity spinning and wet spinning, of which gravity spinning
is preferable for the encapsulation of both hydro- and lipophilic drugs for controlled release.
PCL films are generally preferred out of all methods of fabrication due to slow degradation
and large surface area. Preparation can be via solvent evaporation, roll milling and spin
coating, with solvent evaporation producing the highest degradation rate (Y. Zhu, 2002).
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Hydrogels are drug containing polymer structures that swell upon placement in water and
are most commonly formed using radiation crosslinking. They are primarily designed for
environment-sensitive drug release dependent on such factors as pH, temperature, light,
pressure etc (Qiu & Park, 2012). PCL in its pure form is unsuitable for hydrogel creation given
its lack of reactive groups and its non-ionic nature.
1.3.4.2 PLGA & PLA
As with PCL, these polyesters are quite commonly used in DDSs due to their low toxicity
and ease of tailoring of mechanical properties (Mohamed & van der Walle, 2008).
PLGA microspheres are an attractive option for use as aerosols in pharmaceutical
inhalation devices. Double and single emulsion extraction are primarily used to create
microspheres with the necessary criteria required for such an aerosol. Pluronics™
“microcapsules” are an alternative route to achieving PLGA aerosols (Mohamed F, 2006). In
order to optimise the aerosol for lung targeting, mucoadhesion must be taken into account.
Both PLGA and PLA are poorly adhesive, and to increase the level of mucoadhesion, Chitosan
can be added in the aqueous emulsion phase, or later on by direct mixing with the particles.
The addition of this chitosan has been shown to result in increased lung retention and
prolonged drug action (Takeuchi H, 2001).
Although suitable for oral delivery and inhalation, microspheres are a few orders of
magnitude too large for parenteral administration (IV) and cell internalization.
Nanoparticles/capsules are substituted instead. This is mainly applicable to DNA
encapsulation.
The greatest issue present with polyester microspheres is the burst phase of release
wherein over 60% of drug may be released within the first 24 h. The surface porosity has been
suspected of determining the drug release profile and it has been shown that within the initial
24 hours, a skin envelops the outer surface of the microspheres; terminating the burst release
via “blocking” of the pores (Wang J, 2002). It has also been reported (but not verified using
other drugs) that high drug loading decreases pore size and results in a reduction of burst
release (Sant S, 2005). A practical sample and one relevant to the present research involves
the surface crosslinking of Dexamethasone (DEX)-loaded PLGA with another monomer
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(tri(ethylene glycol) dimethacrylate), and attenuation of burst release was noted (Thote AJ,
2005). However, the drug stability to UV exposure and toxic metabolites may make it
unsuitable for use in vivo.
Instead of altering the surface, we can minimise burst release via use of a core-shell

% Release

structure i.e. coating of the polyester microsphere with another polymer. Variation of the

Figure 3: Encapsulated Cisplatin-loaded microspheres initially (A) and after 7 days (B). Use of shell results in minimal burst
release (C) (Matsumoto A, 2006)

core-shell ratio aids in control over the encapsulation of the protein. A recent study
demonstrates the multi-stage release of cisplatin from PLGA core (Fig. 3) which is governed
primarily by the erosion of the PLA shell (Matsumoto A, 2006).

1.3.5

DDS for Dexamethasone

Glucocorticoids, a class of steroid hormone, are involved in the metabolic function of the
human body and whose main activity is anti-inflammatory. Dexamethasone, in particular, is
currently used in a variety of biomedical field including cell culture, allergology,
ophthalmology, and perioperatively in neurosurgery. Being highly hydrophobic, high doses
are generally required in order to reach therapeutic levels, which often results in side effects
such as osteoporosis and hypertension. Sodium salt of DEX (Section 1.1.8), being hydrophilic
is often recommended as an alternative, however prolonged use may result in sodium
overdosing.
A variety of polymer drug delivery systems (DDSs) have been designed to accurately target
DEX release including natural (chitosan) and synthetic (PEG & PLGA). Poly (ethylene glycol)
(PEG) conjugates have the great advantage in that they are approved by the FDA for clinical
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use. Linear PEG chains result in low concentration of the conjugate drug, and as such,
branched options have been explored. The use of such conjugates was demonstrated by Liu
et al. in which a linear multifunctional PEG-DEX conjugate was synthesized for the treatment
of rheumatoid arthritis. It was demonstrated (in vitro) that the release profile of the conjugate
at pH=5 (characteristic for inflammation) was linear with ~0.5% released per day. However,
under pH=7.4 (characteristic for healthy tissue), there was no release during the 17 days of
testing (Liu XM, 2010). PLGA, like PEG, has been approved for use by the FDA, however, rather
than conjugation, nanoparticles and microspheres are commonly used. PLGA copolymer
ratios can vary from 50:50 to 85:15, and as such, a wide variety of degradation times and
release profiles are possible. In 2010, a DEX-loaded PLGA intravitreal implant (Ozurdex™) was
approved for use in EU states as a sustained release treatment for macular oedema, with
clinical trials showing that, in the short term, vision is improved, and risk of vision loss is
decreased after the first application (Chan A, 2011).
Chitosan, a natural biopolymer, is often used due to its ability to form films, scaffolds, and
microparticles. For films, bilayers and monolayers have been tested, with bilayer films
producing a much slower release. In comparison with conventional ophthalmic steroid drops,
both films resulted in slower release. DEX-loaded chitosan scaffolds are specifically used in
tissue engineering and have been used to reduce inflammation and to induce mesenchymal
stem cell differentiation. Experimentation into Dexamethasone sodium phosphate
microspheres utilisation for treating brain edema confirmed the effectiveness of DEX and
demonstrated an increased therapeutic effect and less severe side effects than other systems
(Turkoglu OF, 2005).
The benefit of the above polymers is that they are well known for their biocompatibility
and lack of side effects. Reports on DEX-loaded PLA, PCL and PLGA implants show no negative
effects of the implantation, barring mild inflammatory effects due to the Implantation itself.
(Urbańska, Karewicz, & Nowakowska, 2014)
1.3.6

DDS for Phenytoin

Phenytoin, unlike Dexamethasone, is used less frequently these days having been
succeeded by drugs such as Lamotrigine and Leviteracetam (Section 1.1.3), and as such very
few modern tests involve the use of Phenytoin. Furthermore, most present-day
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administration of Phenytoin and the prodrug Fosphenytoin is via IV or IM, in which the drug
is in a simple solution. Nevertheless, this drug was chosen for testing due to its availability
and pricing, as well as its long-recorded use for the treatment of epilepsy. To date, there have
only been three DDSs designed for the release of Phenytoin. The first (Fresta, Cavallaro,
Giammona, Wehrli, & Puglisi, 1996) involves the loading of poly(ethylcyanoacrylate) (PECA)
with Phenytoin, in addition to two other anti-epileptics Ethosuximide and Carbamazepine.
Release was biphasic, and it was established that choice of solvent was of greatest importance
in determining final release. Release was only measured for 4 hours by which time
approximately 50 % of the drug had been released.
The following trial (Tamargo et al., 2002) focused solely on Phenytoin, and highlights the
effect of cerebral implantation of Phenytoin (PHT)-loaded Ethylene-Vinyl-Acetate (EVAc) on a
rat model of epilepsy. Release was measured for a total of 102 days and resulted in a total of
3% release, of approximately zero-order for the majority of time, extrapolating to a total
release after 3.5 years. The controlled release of Phenytoin resulted in a statistically
significant decrease in seizure activity (Fig. 4).

Figure 4: Zero order release of Phenytoin over 102 days in vitro (A) with in vitro tests showing a decrease in the number of
seizures with use of Phenytoin (Racine score of 1 or greater suggestive of seizure activity) (Tamargo et al., 2002)

The most recent experimentation (Z. Li, 2007) involved the formulation of spray-dried PHTloaded PCL microcarriers, which was intended for cerebral implantation. It centred on the
effect of formula variation on particle size and PHT entrapment. Release analysis over 23 days
demonstrated multi-phasic release with 80% (maximum) release noted at t=20 days.
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1.4 ADDITIVE FABRICATION FOR DRUG RELEASE
1.4.1

3D printing and drug delivery

The first 3D printed tablet, Spritam®(active ingredient: levetiracetam), was approved by
the FDA in August 2015, and has created a precedent for the use of 3D printed drug delivery
systems. The unique ability of additive manufacturing to dispense low volume with precise
accuracy and fine spatial control allows for the creation of intricate scaffolds with multiple
active ingredients, which, in turn, can create complex and tailored drug release profiles.
There are presently two main forms of technology used in the development of 3D printed
DDS: 3D inkjet and powder systems, and Fused Filament Fabrication (FFF)/Fused Deposition
Modelling (FDM) [trademarked by Stratasys]
3D Inkjet printing works in a manner similar to that of an inkjet printer in that it places
droplets of liquid onto a surface in a precise configuration. It differs in that after one layer
dries, a second may be deposited on top of it. The powder bed system is slightly different in
that the droplets of ‘ink’ contain a binder which, when placed upon the surface (in this case a
bed of powder), binds the layer into a specific geometry.
FDM employs thermoplastic polymers such as PLA and PVA and is what is generally
understood when considering consumer 3D printing. A filament or pellets are fed into the
printer which melts and extrudes the polymer at a specific flow rate. Once deposited, the
material cools and solidifies.
Once printed, the DDS comes in a variety of forms, including implants, tablets and
transdermal delivery systems.
3D implants have been developed over the last 10 years, from the simple monolithic
levofloxacin-loaded PLA implant in 2007, to a more complex two-component implant which
utilises gold nanorods: programmed such that a specific laser wavelength will rupture the
external shell and release the drug. The Intelligent Polymer Research Institute (IPRI) itself has
worked in this field (Rattanakit, Moulton, Santiago, Liawruangrath, & Wallace, 2012), in which
it tested the effect of varying layering techniques on release profile (Figure 5). Medical
implants such as stents and catheters can also benefit from 3D printing. Whereas in the past,
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stents and catheters were treated with active solutions via spray coating, 3D printing allows
for precise and repeatable coating.
Work on 3D printed tablets started as early as 1998, in which powder bed printing was
used to achieve low drug deposition (0.34 ng per droplet) (Katstra et al., 2000). 3D printed
tablets offer a distinct advantage over regular compressed tablets in that they allow for

Figure 5: Schematic of sandwich layering design (A) and corresponding layer-dependent drug release profile
(B) (Rattankit et al., 2012)

complex release profiles via altering layering, porosity and geometry. Recently, FDM has been
used to vary the infill of tablets, directly affecting the release time.
Transdermal delivery is a new form in the field of 3D drug delivery. It involves the
puncturing of the skin with drug-loaded biodegradable microneedles and offers the
advantage of bypassing first pass metabolism. Geometry and hardness can be tailored, as can
the position of the drug in the needle. (Prasad & Smyth, 2015)
1.4.2

3D printed DDS

1.4.2.1 Tablets
In the last 10 years over 15 variations of 3D printed tablet have been designed, which
generally fall under two forms of fabrication: Inkjet systems (drop-on-powder) and nozzle
based deposition systems (FDM) (Jonathan & Karim, 2016; Prasad & Smyth, 2015). Release
profiles varied including zero order delayed sustained and burst release. So too did the drug
of choice including (but not limited to) analgesics e.g. acetaminophen (paracetamol); antiinflammatories e.g. Prednisolone, and anti-epileptics e.g. Leviteracetam. 3D printing allows
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for the creation of complex shapes such as toroids which in the past were extremely difficult
to produce via the traditional compression method. Yu et al. were able to print such a tablet,
with a thin barrier layer on the surface. This not only produced a zero-order release profile
but also showed minimal burst release (Yu D-G, 2009) (Fig. 6)

Figure 6: Schematic of toroidal tablet (A) which demonstrates zero-order release with minimal initial
bust release (B) (Yu D-G, 2009)

1.4.2.2 Transdermal Needles
The benefit of transdermal syringes has been known since 2001 wherein it was shown that
there was minimal pain associated with microneedles (Kaushik S, 2001). However, the
physical properties (size, shape, material) of these needles caused difficulty in manufacturing,
which was later resolved with the advancement of 3D printing. Through the use of
Stereolithography and inkjet printing, Boehm et al. were able to create needles with
antimicrobial properties and, in addition, concentrate agent loading on to the tip of the
needle, thereby minimising the effect on microneedle structure which would normally be
seen using traditional methods such as dip-coating (Boehm RD, 2014).
1.4.2.3 Implants
The concept of 3D printed implants has been around for over 20 years, and since 2006 9
different implants have been designed. As with tablets, multiple drugs have been tested
including Dexamethasone-21 (Zhang, 2014) and Rifampin (Gu Y, 2012; Huang W, 2007). The
work by Huang et al. was able to produce implants with bimodal release i.e. the Levofloxacin
outer later produced immediate release (t<1 day), whereas the Rifampin inner layer
presented delayed release (t=8 days). Sandler et al. were able to utilise both hot melt
extrusion (for filament creation) and a traditional 3D printer to create a drug eluting catheter
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that showed greater inhibition of biofilm formation (85%) than that of a similar coated device
(25%) (Sandler N, 2014).
1.4.3

DDS for epilepsy

Polymer implants for the treatment of epilepsy have been extremely popular in the last
few decades (Halliday, Moulton, Wallace, & Cook, 2012) and have incorporated a variety of
anti-epileptic drugs (AEDs) including Carbamazepine (N.S. Barakat, 2006), Clonazepam (Y.I.
Jeong, 1998) and Phenytoin (Z. Li, 2007). Device formation is also extremely varied including
monolithic structures formed from drop-casting, electrospinning and melt extrusion; and
particulate structures formed via spray drying, electrospraying and dialysis. One of the
greatest goals in the creation and use of anti-epileptic drug delivery systems is the long-term
amelioration of seizures in-vivo. For a long time, it had been difficult to achieve lengthy
amelioration, however recent advances have produced systems that demonstrate long term
release of AEDs (t>250 d) in vitro and seizure amelioration of over 6 months in a rat model
(E. Pritchard, 2010). The fusion of 3D printing and epilepsy treatment is in its infancy, and, as
of yet, no 3D printed implants for the treatment of epilepsy have been created. However,
there have been advances into 3D printed epileptic DDSs such as Spritam® (Section 1.4.1) and,
more recently, a team recently printed a Carbamazepine-loaded sustained-release scaffold
(Lim, Chia, Kang, & Yap, 2016).
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1.4.4

Outlook

As discussed above, Epilepsy research is highly developed and a plethora of anti-convulsant
drugs have been created for symptom management. The choice of anti-convulsant is based
on seizure syndrome, co-medications, age, and other factors. Once a second seizure has
occurred, epilepsy is usually treated with daily medication, possibly for the rest of the
patient’s life. Seizures are often a short-term complication of neurosurgical procedures
performed for other reasons, such as tumour surgery, and necessitate administration of
prophylactic medications for some months. One of the greatest issues with daily medication
is patient compliance and the maintenance of correct dosage. Drug administration is usually
oral via capsule or suspension or may be introduced parenterally via IV.
Recently, researchers at St Vincent’s Hospital have developed a neural implant which
accurately predicts seizures in humans (Kuhlmann et al., 2010). Further research has been
done into the electrostimulation of a polymer implant which would, in turn, release an antiinflammatory loaded within it (Stevenson, Moulton, Innis, & Wallace, 2010). The replacement
of the anti-inflammatory agent with an anti-epileptic such as Phenytoin would potentially
allow for instantaneous treatment upon occurrence of a seizure. While this is undoubtedly a
step forward, three problems present themselves.
The first is the necessity for periodic replacement of the active agent. This involves invasive
surgery to re-implant the device when the drug is exhausted due to stimulation and release.
In the case of non-stimulation, the device would still require periodic replacement as the drug
may have a finite lifetime.
The second issue is that of the use of non-biological material in the brain. While stringent
investigation has been undertaken to ensure that the electrodes and polymers are safe, there
is always a preference for using biodegradable materials, whether they be natural e.g.
chitosan, or synthetic e.g. PLA.
The third issue relates to the process and complications of the neurosurgery itself, and the
requirement for different medications or treatments at different stages of the condition. For
example, in the period immediately after a neurosurgical procedure, steroids are given for a
short period – usually some weeks – to supress the sometimes-damaging inflammation which
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may occur post-operatively. Anticonvulsants such as phenytoin may then be given for 3-6
months to reduce the risk of recurrence of post-operative seizure. These complex regimens
create problems with compliance, and the systemic effects of both these agents can be
significant. Local administration would circumvent these issues.
A possible solution, and the one which forms the basis of the current research, is the
implantation of a 3D-printed polymer implant, which is doped with a combination of antiepileptics as well as an anti-inflammatory (Dexamethasone). The use of 3D printing is of
fundamental significance for the fabrication of the proposed polymer implants; exploiting the
capacity of 3D printing to accurately position, arrange, and build up the layers of drug-loaded
polymer will enable the formation of extremely complex but effective drug release profiles
that otherwise could not be achieved using conventional approaches. The polymer implants
will effectively be “encoded” with release profiles via 3D printing. By a) varying the layering
thickness, porosity, and materials themselves, and b) changing the concentration of drug
present as well as its position throughout the polymer, the potential exists to further control
the drug release profile.
The proposed polymer implant will permit not only rapid release of the anti-inflammatory
agent, thereby reducing any detrimental effects of the implantation on the brain but will also
generate a complex long term release profile for the anti-epileptic agent (ideally over a period
of twelve or more months). The implant would require periodic replacement, however the
date could be determined in advance, and the procedure itself would be relatively less
invasive than other brain implants, as it would require minimal surgery, and, given its
biodegradability, not require extraction. It is also anticipated that this implant may be used
as a ‘one-off’ postoperative insert, to avoid the damaging effects of brain oedema and risk of
seizures developing after routine neurosurgical procedures.
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1.5 RESEARCH AIMS AND OBJECTIVES
This MPhil research project focuses on the development of a 3D-printed polymer implant,
doped with a combination of an anti-epileptic (Phenytoin) as well as an anti-inflammatory
(Dexamethasone), and to be used for the prophylactic treatment of epilepsy. The
practicability of building and efficacy of such an implant is of primary concern.
In order to achieve such an aim, a number of objectives must be realized:
1. The selecting and printing of drug-loaded polymers corresponding to the preferred
drug release profiles of our drugs. Chapter 2
2. Using the chosen polymers, the variation of a printed scaffold’s morphology and
properties in order to achieve tailored profiles for our individual drugs. Chapter 3
3. The creation of a core-shell structure, in effect a Phenytoin-loaded scaffold encased
in a Dexamethasone-loaded shell, that allows for the dual release of both our drugs
simultaneously and wherein the completed structure would allow for a unique
combination of release profiles tailored towards the individual dependent on their
needs. Chapter 4
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2. EXPERIMENTAL: DEVELOPMENT AND OPTIMISATION OF 3D PRINTED
DRUG-LOADED POLYMER IMPLANTS
2.1 INTRODUCTION
2.1.1

Background

Research into DDSs has been active for many decades, and detailed studies (and
metastudies) have been able to show the effect of drug and polymer type on drug release
for a large variety of drugs (Section 1.2). However, the use of FDM in the field of
pharmaceuticals is relatively new compared to consumer goods. In the pharmaceutical field
research efforts are mainly focused on the fabrication of oral dosage forms, and little
research has been made into the 3D printing of drug loaded implants, let alone for dualdrug release. The major advantage of implant 3D printing is the ability to form geometries
with nearly any shape so that the implant could be printed individualized for each patient.
This shape adaption might be especially first stage for FDM-printing of drug-loaded
polymers is the choice of drug and polymer and the creation of a drug-loaded filament.
Although polymer incubation in a drug solution is an option; preferential for its lower risk of
drug or polymer degradation due to lack of thermal load, the disadvantages (low drug load,
expensive drug solution, and few viable drug-polymer options) have resulted in Hot Melt
Extrusion (HME) being the preferred method of production of these filaments. (Kempin et
al., 2017). Goyanes et al. are presently the leaders in this field, having tested multiple
polymers, drugs, scaffold geometries (important for application sites with a high variability
in patient’s anatomy, e.g. the paranasal sinuses (Kantarci et al., 2004)) and have successfully
demonstrated the ability of double extrusion of two different filaments for the FDM of
capsule-shaped oral devices, which allows the combination of two different drugs in layers
or in coat-core-designs (Goyanes et al., 2015), which shall be investigated for our specific
case in Chapter 4.
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2.1.2

Objective

The first steps in designing a new drug releasing implant are as follows:
a) Choice of viable materials: drugs and polymers
b) Optimisation of the new manufacturing process (FDM printing)
c) Testing and comparison of the newly printed implants
d) Variation in material (polymers) and structure (scaffold morphology)
The first steps in designing a new drug releasing implant include the choosing of viable
materials (drugs and polymers), the optimisation of the new manufacturing process (FDM
Printing), the testing and comparison of newly printed implants, and the variation in the
material (polymer) and structure (scaffold morphology) of the implants.
Choice of materials has already been completed, with PCL and DL-PLA being the optimum
polymers for testing due to price, release profile, biodegradability and reproducibility (see
Section 1.3), and the drugs (Phenytoin and Dexamethasone) having been chosen by the
clinicians.
Chapter 2 analyses the viability of using HME and FDM for creating drug-loaded polymer
implants, confirming the ability to accurately reproduce the final product and testing whether
the printing process itself changes the inherent character of the drug itself. We also attempt
to optimise the printing by looking at variation in polymer creation methodology, printing
parameters such as pressure and temperature, and tip size.
Chapters 3 and 4 look into the testing and comparison of newly printed implants, as well as
looking into the effect of variation in material and structure on the final drug release profile.
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2.2 METHODS
2.2.1

Polymer Preparation

The first part of this work involves the development and optimisation of drug-loaded
polymers. One of the greatest factors affecting drug release is the drug-loaded polymer itself.
Polymer type, molecular weight, and ratio (for copolymers) will not only affect the release
order (1.3.2), but will also affect rate of release, and degree of burst release.
Practical considerations must also be taken into account, including solubility, melting
temperature (glass transition temperature), biodegradability and sample uniformity.
Preparation of a thin-film biopolymer, suitable for initial drug release and degradation
studies, as well as for polymer stock in printing, can be achieved via a variety of methods
including dip-coating, spin-coating, drop-casting, and Langmuir–Blodgett.
Drop Casting: dropping of solution and spontaneous solvent evaporation.
Film thickness: proportional to solution concentration
Pros: very simple, no waste of material
Cons: limitations in large area coverage, thickness hard to control, poor uniformity
Spin coating: dropping on spinning substrate.
Film thickness: dependent on many controllable parameters such as dω/dt, ω, t, …
Pros: good uniformity/reproducibility, good thickness control
Cons: waste of material, no large area, film dries fast→less molecular ordering
Dip coating: substrate is dipped into the solution and then withdrawn at a controlled
speed.
Film thickness: determined by balance of forces at the liquid-substrate interface
Pros: good uniformity, very thin layers, large area coverage
Cons: waste of material, time consuming, double side coverage
Langmuir-Blodgett: based on hydrophobicity/hydrophilicity.
Pros: excellent control of thickness, homogeneity over large areas, multilayer
structures with varying layer composition
Cons: only amphyphillic molecules can be deposited, non-trivial set up
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Drop-casting was chosen for this project due to its simplicity, and chloroform was found
to be a suitable solvent for the majority of polymers and drugs. Burst release was preferable
for the short-term release of Dexamethasone, and as such PCL, which exhibits such
properties, was selected for trials. Ideal release for Phenytoin would be linear (zero-order
release) with complete release over a period of approx. 12 months. A suitable candidate was
found which contained a mixture of high (70/130 k) and low (5 k) molecular weight DL-PLA
(Kunou et al., 2000). 3D printing has not yet been thoroughly explored in its use for creating
drug-loaded polymer implants. As such it is necessary to create both traditional (drop-cast)
and 3D-printed samples to analyse the effect the printing (in contrast to the traditional
method) has on the drug release.
2.2.1.1 Optimisation of drop cast polymer preparation
Comparison testing (see Section 3.2.3) and preparation of polymer stock require the use
of Drop (Solvent) Cast Evaporation. A variety of techniques have been established over the
decades (Siemann, 2005), and it was decided to use the format utilized by (Zhang, 2014) which
involved evaporation in fume hood for 24 h then placement in a vacuum oven at room
temperature for a further 24 hours. Variations in the traditional method were also tested:
a) Evaporation in the fume hood for 80 min at a temperature of 80℃
b) Evaporation outside a fume hood for 24 hours (under a low-strength extractor fan)
Variations in polymer molecular weight (45k vs. 10k PCL) and polymer type (PCL vs DL-PLA)
were also tested.
2.2.1.1.1 Preparation of DEX-loaded PCL
Drop Cast samples for comparison with 3D Printed samples: To prepare 25 ml of 2% Dexloaded PCL, 250mg of PCL (Sigma, Germany) was dissolved in 25ml of Chloroform (Sigma
Aldrich). Dexamethasone (Micronised, USP, from Spectrum Chemical) was added according
to a desired ratio e.g. Dex:PCL = 1:50 requires 5 mg of Dex. Samples were stirred for one (1)
hour at RT and then 5 ml of solution was pipetted into individual petri dishes. The petri dishes
were left to evaporate inside a fume hood for 24 hours and then placed in a vacuum oven at
RT for 4 hours to remove remaining solvent.
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Polymer stock for Printing (Bioplotter): PCL (2 g) was dissolved in Chloroform (40 ml). As
above, Dexamethasone was added according to desired ratio. The solution was stirred for one
hour and transferred to a large petri dish and the evaporation procedure was done as above
for the individual samples. A lower volume of Chloroform was used in order to decrease
evaporation time.
2.2.1.1.2 Preparation of PHT-loaded DL-PLA
Polymer stock for Printing (Bioplotter): A DL-PLA mixture was formed by combining 1.6 g of
DL-PLA 20 (2.0 dl/g, Corbion) with 0.4 g of DL-PLA 04 (0.4 dl/g, Corbion) which was then
dissolved in Chloroform (40 ml). Phenytoin (St Vincent’s Hospital) was added according to
desired ratio. The solution was stirred for one hour and transferred to a large petri dish and
evaporated as in Section 2.2.1.1.1. Figure 7 shows drop cast films of DL-PLA (Fig. 7A) and PCL
(Fig. 7B).

Figure 7: Drop cast polymer sheets | Left: DL-PLA, Right: PCL
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2.2.2

3D Printing

A large portion of the research (Chapter 3 & 4) required the use of a FDM printer for the
printing of DEX and PHT loaded polymer scaffolds. The KIMM SPS-1000 Bioplotter is a 3-axis
extrusion assembly with custom software and was utilized for this project (Figure 8). Unlike a
standard FDM printer, which uses as its input material extruded polymer at either 1.5 mm or
3 mm, the bioplotter combines both HME and FDM in one system via the use of a heated
stainless-steel barrel. The barrel contains the drop cast polymer stock (3.2.1.1.1. & 3.2.1.1.2),
cut up in small pieces to ensure that it fits in the barrel and melts uniformly. The heated barrel
(0-400°C) allows for tips varying in diameter from 100 microns to 500 microns. It is attached
to a pressure control system which allows variation in pressure from 0 to 550 kPa. Nitrogen
is used as the pressurising gas.

Figure 8: Photographs of KIMM/M4T SPS1000 Bioplotter (Zhang, 2014)
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2.2.2.1 Optimisation of 3D printing
The KIMM Bioplotter is required to be calibrated for each new polymer that is used. Each
polymer has a different viscosity and melting point (some, such as DL-PLA, being noncrystalline, have no melting point), and it is necessary to vary such factors as temperature,
pressure, and feed rate, such that all prints can be optimised for uniformity. In the below
methodology, all factors were kept constant barring the testing variable e.g. feed rate.
2.2.2.1.1 Preparation of Dex-loaded PCL Printed Scaffolds
2 g of Dex-loaded PCL was created via drop-cast evaporation (Section 2.2.1.1.1). The
polymer sheet was removed with a scalpel and cut into approx. 5x5 mm squares before being
placed in the extrusion tube. This is required in order to allow the entire polymer to pool in
the bottom section of the tube after melting, rather than stick to the sides. A 27 g (310 um)
tip was used for extrusion (Fig. 11). Use of a tip of certain diameter does not guarantee a
filament extrusion of this size. This is dependent on other factors such as temperature, tip
height from base, and pressure. Use of a different tip would require recalibration of these
parameters. An ‘stl’ file was created in the proprietary software, “Bioplotter”. This software
allows the setting of scaffold parameters such as porosity (spacing) and layer height. A simple
hatch design was used for ease of parameter alteration. The file was then saved and imported
into “Mach3 CNC Controller”. This is the software used to control the KIMM SPS-1000
Bioplotter hardware: Feed rate (speed in mm/min), tip height, and position. The polymer was
extruded at 120°C with a pressure of 500 kPa.
2.2.2.1.2 Feed rate
Maintaining constant temperature and pressure allows us to change the feed rate of the print.
This is the determining factor in the rate at which the sample is printed. Samples were printed
at varying feed rates from F=100 to F=300.
N.B. Feed rate has no formal definition, and differs depending on the make, model and type
of machine used i.e. CNC or FDM printer. For some printers, the units are mm 3/s, for others
mm/s (even holding the assumption that the units are metric). The KIMM Bioplotter is a nonstandardised printer based off a CNC machine, so it is unknown what the units represent.
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2.2.2.1.3 Pressure
Pressure of the system defines the rate at which the polymer is extruded and is
proportional to feed rate. Increasing the pressure allows one to increase feed rate. Peak
pressure for the system is ~500 kPa. This itself was not optimised and was generally set at the
maximum pressure at which the polymer and tip size combination allowed for extrusion.
2.2.2.1.4 Tip size
Stainless steel tips of various size were supplied with the KIMM Bioplotter (Fig 8). In
addition, custom nickel and titanium tips (Fig, 11 A & B) were fabricated within the lab by the
team of Stephen Beirne. Tip size defines the degree to which one can produce fine structures.
However, tip size choice is constrained by the polymer properties. Use of a 27-gauge tip with
DL-PLA results in blockages, and, as a result, 24 g tips are used. Furthermore, the DL-PLA
adheres greatly to stainless steel tip, and as such, tip height and appropriate platform material
must be chosen in order to ensure proper deposition.

Figure 9: Stereomicroscope image of tip options | A: Custom titanium tip | B: Close-up | C: Supplied Stainless Steel tip
Note: Use of SLM (selective laser melting) for the custom tips (A&B) results in rough surfaces at the micrometre level. White
strand in bottom right of 8C is left over hardened polymer.

2.2.2.1.5 Tip Height
The height of the tip above the platform is set manually and dependent on all other
properties. The tip should be lowered until it reaches a height in which a uniform row is able
to be printed. If there is no point at which this occurs, other parameters such as temperature
and pressure must be altered.
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2.2.2.1.6 Temperature
Starting at a temperature of 80 ℃ (65 ℃ is the melting point of PCL), and using a 24g tip,
straight lines of polymer were printed at temperature intervals of 10℃ until 120℃ and line
widths were measured.
2.2.2.2 Effect of Printing at Elevated Temperatures on Drug Bioavailability
Powdered samples of DEX and PHT were heated to 170°C for a period of 4 hours, after
which they were analysed via Fourier-transform infrared spectroscopy (FTIR) and Nuclear
Magnetic Resonance (NMR) and compared with controls.
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2.3 RESULTS & DISCUSSION
2.3.1

Optimisation of drop cast polymer preparation

Evaporation of the PCL in the fume-hood resulted in ripples and sheet thickness variation due
to air circulation (Fig. 14A). Although this was lessened via the use of simultaneous heating,
the quick rate of evaporation resulted in strong film adhesion to the glass plate which
presented difficulties when attempting to remove the samples (Fig. 14B). It was decided that
in order to create large uniform samples the best option was to evaporate for 24 h outside
the fume hood (Fig. 14C).

B

A

C

Figure 10: Drop Cast Technique comparison PCL 45k (A) Evaporation fume hood 24h. (B) Evaporation fume
hood + melt @80C for 80min. (C) Evaporation in air 24h

Polymer type and molecular weight can also affect sheet appearance (Fig. 15). PCL synthesis
produced a translucent film (Figs 15 A and B) whereas DL-PLA synthesis produced a
transparent film (Fig. 15C). Unlike 45k molecular weight PCL (Fig. 15A), which produced
smooth, tough sheets, use of the 10k molecular weight PCL (Fig. 15B) resulted in extremely
brittle sheets which crumbled upon handling.

Figure 11: Polymer Type & Mw | A: PCL 45k | B: PCL 10k | C: DL-PLA
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2.3.2

Effect of Printing at Elevated Temperatures on Drug Bioavailability

Given the novelty of FDM use in the preparation of drug-loaded polymer implants, it is
necessary to consider the effect this form of fabrication may have on the final product. Unlike
solvent extrusion, melt extrusion requires the use of high temperatures and it must be
determined whether this influences the pharmacological activity of the drugs. Although the
extrusion temperatures within this project (max:170°C) are far below the melting points of
both drugs (Budavari, 2001) there is no guarantee that the high temperatures will not have
an effect. Ideally, in-vitro assays specifically tailored to the drug would be utilised to
determine whether the drug activity has been affected. However, it was established that it
was sufficient to show there was no change to the chemical structure of the drugs.
Powdered samples of DEX and PHT were heated to 170°C for a period of 4 hours, after
which they were analysed via Fourier-transform infrared spectroscopy (FTIR) and Nuclear
Magnetic Resonance (NMR) and compared with controls. NMR takes advantage of the spin
states of protons (and, to some extent, other nuclei) to identify a compound. FTIR, on the
other hand, utilises infrared radiation to cause changes in the vibrational states of organic

Figure 13: FTIR comparison of DEX (A) and PHT (B) powder pre- and post-heating| Black/Green: Pre-heating, Red/Blue: Postheating @150°C for 4 hours

Figure 12: NMR comparison of DEX (A) and PHT (B) powder pre- and post-heating|
Top/Red: Pre-heating, Bottom/Blue: Post-heating @150°C for 4 hours
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molecules. The results (Fig 20 & 21), show no effect on drug structure after heating. For the
NMR graphs, identical height of peaks as well as number and placement on both the heated
and non-heated samples indicates no alteration of the drugs’ chemical structure. As with the
NMR results, superficial analysis of the FTIR graphs indicates no change in the chemical
composition of the drugs, represented in the graphs by identical peaks. While spectrally
similar, it is important to note that there is an offset between the two tests, proportional to
the transmittance reading. The most likely cause for this discrepancy is the movement of
some part of the optics between collection of the two spectra.
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2.3.3

Optimisation of 3D printing

2.3.3.1 Feed Rate
Through the range of F=120 to F=240, a constant increase in feed rate, resulted in a linear
decrease in row width (Fig. 16 A-C, and Table 4). From F=260 and above (Fig. 16 D-F), the row
width appears to remain constant at ~320 μm; unsurprising given that a gauge 24 (310 µm)
tip was used. Row thickness increases at the end of rows, due to a reduced feed rate required
for turns, and the initial and final accelerations and decelerations. No repeated
measurements were taken for the feed rate (Section 2.2.2.1.2) nor the temperature (Section
2.2.2.1.6) analysis.

Row Width vs Feed rate
700

Row Width (um)

600
500
400
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y = -0.8417x + 623.17
R² = 0.9992

200
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0
0
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Row Width (um)

Linear (Row Width (um))

Table 1: Row width vs Feed Rate| PCL+Dex w/ 24g tip, T=100°C, P=100kPa from F=120 to F=240

Feed: 120

Row width: 523um

Feed: 180

Row width: 470um

Feed: 260

Row width: 334um

Feed: 280

47 width: 320um
Row

Feed: 240

Feed: 300

Row width: 422um

Row width: 327um

Figure 14: Stereomicroscope image of Feed rate vs row width | PCL+Dex w/ 24g tip, T=100°C, P=100kPa

2.3.3.2 Temperature
PCL has a melting point of 65°C, however, the viscosity of the polymer will linearly decrease
with the temperature, corresponding to a linear increase in width (R 2=0.9957) (Fig. 18 and
Table 5). Minimum width for a 24 g tip is 311 μm, which, given the conditions, could be
achieved at a temperature of 72°C.
2.3.3.3
T=80°C

W=401um

T=90°C

W=502um

T=100°C

W=635um

T=110°C

W=755um

T=120°C

W=842um

Figure 15: Stereomicroscope image of Temperature vs row width 80°C-120°C | PCL+Dex
P=100kPa F=300 Tip=24g
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Table 2: Row Width vs Temperature | PCL+Dex P=100kPa F=300 Tip=24g T=80°C-120°C

48

130

Final Drop Cast and Printed Scaffold Structures
Figure 16 highlights the variety of drug-loaded polymer constructs used for
experimentation, including drop-cast sheets (A & B), porous scaffolds (C & D), and shell
structures (E & F). The methodology for creating such structures is laid out in Chapters 3 & 4.
Figure 16A & B are stereomicroscopic images of Drop Cast PCL loaded DEX and PHT. The dropcast sheets were translucent to opaque depending on thickness with slightly rough texture
and, as can be seen specifically in B, may contain deposits of drug if not completely dissolved
initially. Figure 16 C & D are images of DEX-loaded PCL and PHT-loaded DL-PLA scaffolds
respectively. The PCL appears pale yellow/white and can be brittle dependent on the
molecular weight of the initial polymer source. As can be seen on the top and bottom of the
scaffold in C), large amounts of polymer are deposited upon change of direction. This can be
minimised by increasing the feed rate around corners. The DL-PLA scaffold (intended for core
use in Chapter 5) appears transparent and allows for accurate printing with little variation in
row thickness. Figure 16 E & F show a top (E) and cross-sectional (F) view of a PCL base,
intended for use in a shell structure. The final structure includes a DEX-loaded lid, with the
two PCL parts sealed and encasing a PHT-loaded DL-PLA scaffold such as that seen in D). The
porosity appears to increase as the number of layers in increased. A likely reason is the
inability to set each layer’s height such that they are deposited directly on top of each other
with uniform layer thickness.

Table 3: variety of drug-loaded polymer constructs used for experimentation, including drop-cast sheets (A
& B), porous scaffolds (C & D), and shell structures (E49
& F)

2.3.3.4 Reproducibility
3D printing is unique in the field of fabrication in that, rather than producing mass samples,
it allows for the quick creation of tailored samples. Despite this, it is still important that we
should be able to reproduce a near identical sample several years down the track, by following
a set of established protocols. Ideally, in the future, one would be able to input a
predetermined set of parameters such as drug type, dosage and required release profile, and
create an implant that follows that unique profile. In order for this to occur, each step in the
process must result in a product that it reproducible. Bulk batches of polymers and drugs
should be able to show the same physical and chemical properties within and between
batches. Polymer samples often state an approximate molecular weight across a range (it
cannot be calculated empirically). This variance should not have an effect further down the
line in production. The synthesis should result in consistent product within and between
batches. A non-uniform sample may be just as problematic as variance between batches. In
this case, although the film may have had non-uniform thickness, the processing in the
fabrication stage resulted in a homogenous sample. Once all parameters are set, the final
product should not vary in size nor mass; no matter the time of fabrication.
Although every sample may be identical up to this stage, it is no guarantee that the analysis
will show uniform results: in our case, drug release profiles. As such, it is necessary to repeat
testing of single samples e.g. HPLC/UV-Vis, and to create replicate samples. When testing a
parameter, at least 3 identical samples should be tested, and each analysed repeatedly. As
such, we can understand the inherent variance in the system, and diagnose whether our
results are outside the expected value.
For this project, the fabrication stage presents the greatest issue. The printer used during
this project lacks the calibration functions required to produce uniform samples. Although
the x and y axis are computer defined, the z-axis can be adjusted by hand and the extruder
nozzle can be removed and replaced. Whilst beneficial for extruding various polymers at
various thicknesses, this also ensures that the tip height (distance between tip to build
platform) is not constant, nor able to be kept constant. Although one is able to create fairly
uniform samples within a single print session, there is often large variance between prints.
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This variation in size correlates to a large variation in release rate (Fig. 19), wherein thinner
samples produced in March resulted in quicker drug release than that of the February
samples. A more in-depth analysis into the variation in printing was not conducted. A possible
solution, and one which is present on other printers, is a simple laser distance gauge, allowing
one to keep tip height constant, and ensuring uniformity in samples.

FEBRUARY VS MARCH TESTING-3
LAYER CLOSED
DRUG RELEASED (%)
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0
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Figure 16:Variance in release profiles due to variability in printing. Comparison of samples from February and March| n=3;
error bars are on the order of graph point size
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2.4 CONCLUSION
In this chapter, it was able to be shown that 3D printing is, in fact, a viable option for the
creation of 3D printed drug-loaded scaffolds. We were able to show that we could
accurately and easily alter the size of rows in a scaffold via changes in temperature and feed
rate. Furthermore, all the parts necessary for the next two stages of the experiment were
able to be successfully printed. More importantly, it was able to be demonstrated that the
use of high temperatures while printing did not, as far as could be determined, affect the
structure of the drugs loaded within the printed polymer. A procedure was optimised for
the creation of drop-cast polymer sheets, which will be used as for comparison in the next
chapter as well as for printer stock.
However, it must be noted that an issue was highlighted here that is representative of a
much larger issue within the biofabrication field and indeed the 3D printing community as a
whole: that of standardisation and reproducibility. As of March 2018, there are no
standardisation protocols in place for a) the creation of bioprinters, b) the creation of
bioinks, polymers, and other materials, c) the testing of any of these products. Without
these protocols, there is no way to compare results accurately or ensure that your product
meets certain basic requirements. This will need to be addressed before biofabrication
properly enters into industry.
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3. EXPERIMENTAL: EFFECT OF PRINTED SCAFFOLD PROPERTIES ON DRUG RELEASE
3.1 INTRODUCTION
3.1.1

Background

When designing an implant for drug release, the targeted release profile of the drugs
(release rate, duration of release, type of release) is the determining factor in choosing both
the material and structure of the scaffold (See Section 1.3). There do not appear to be any
studies researching the effect of 3D printed scaffold property variation on drug release.
3.1.2

Objective

Having tested the viability and practicability of using 3D printing as the form of
manufacturing for the creation of drug-loaded polymer implants (Chapter 2), we are now
required to compare the release profile of a standard printed sample with that of the dropcast sheets optimised in Section 2.3.1. This is to ensure that the new methodology does not
alter the drug release profile of the drug-loaded implant in an unforeseen and unpredictable
manner. Following this, the chapter delves into the effect of a) scaffold morphology, and b)
drug and polymer variation, on the release profile of printed samples.
3.1.2.1 Scaffold Morphology & Property Variation
This testing of the intrinsic properties of a scaffold is necessary in order to establish the
most influential properties in polymer drug release; and, having done so, to tweak these
properties such that a tailored release profile may be created. While the release profile may
also be altered via external printer properties such as temperature, it is preferential to set
these parameters at the start of printing in such a way to ensure a smooth uninterrupted
print, and to alter the profile using the inherent properties of the print itself. The different
physical properties investigated are shown in Figure 24 and include 1) porosity/grid spacing
(related to the width of the gap between rows of the lattice), 2) open or closed (determined
by whether or not rows are linked), and 3) number of printed layers or height of the scaffold.
Although there are a variety of possible shapes that can be printed, in order to ensure ease
of print and uniformity of samples, a simple lattice structure was created. All drug release
measurements and analysis were done using Dex loaded PCL polymers.
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A

B

C

Figure 17: Schematic of different scaffold properties. (A) Lattice spacing. (B) number of layers/ height. (C) Open vs. Closed Scaffold

3.1.2.2 Drug & Polymer variation
The fields of pharmacology and drug release are extremely wide and there is a plethora of
methods to modify drug release, including passive vs active systems, PEGylation, system type
(e.g. matrix, capsules, osmotic pump), particle size, temperature and pH (Bruschi, 2015).
Furthermore, each drug and polymer has its own set of physical and chemical properties
including solubility, hydrophobicity, crystallinity and inherent viscosity. While some of these
may only have a direct impact on scaffold fabrication, others have a large effect on the nature
of the drug release itself. These methods are outside the scope of this project, which focuses
purely on the effect of physical scaffold properties in determining the release. However, given
the necessity to produce a dual-drug/polymer system, two different drugs and polymers
would need to be chosen. Past research (Kunou et al., 2000) supported the use of PCL and DLPLA composite for this project; however, it was necessary to verify that the polymers do in
fact produce the intended drug release profile i.e. an initial release of the DEX followed by a
sustained release of PHT. Furthermore, it was necessary to analyse whether the use of a
separate drug would affect the release profile.
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3.2 METHODS
3.2.1

Preparation of Drop Cast, 3D Printed and Shell Structures for Drug Release
Measurements via HPLC

The implant is intended to be surgically placed upon the cerebral cortex (within the
subarachnoid space), after which the scalp will be sutured, and the implant left to degrade
and release drugs until such a time when the loaded drugs have been exhausted, ideally
greater than 12 months. Real time analysis of drug release in vivo is impractical, and perhaps
impossible at this present stage. As such, we are required to replicate the conditions found
within the brain in vivo. Within the subarachnoid space is found cerebrospinal fluid (CSF), a
clear colorless fluid which provides basic and immunological protection to the brain in the
skull. Initial intentions were to use artificial CSF (aCSF) for the in vivo medium into which the
implants would be placed. However, it was deemed preferable at this early stage of testing,
to use Phosphate Buffered Saline (PBS) solution due to its ease of manufacture (in this case,
simple dissolution of pre-made PBS powder in water), regular use within biological research
(due to a similar osmolarity and ion concentration as that of the human body), and price. PBS
solutions can vary slightly with contents and ion concentration but have a very similar water
content and osmolarity to that of CSF. It is almost important that, as with the majority of other
biological tests, we keep the temperature at a temperature of 37℃. This is done to ensure
that the rate of drug release from the polymers (which is dependent on temperature) is
similar to that which would occur in-vitro.
3.2.1.1 Printed samples
For the basic scaffolds, polymer samples were weighed and placed in separate vials with
1 ml of PBS. For the shell/core samples, lid and base were measured together, followed by
the PLA scaffold. Following this, the shell is assembled as in Section 4.2.1 and then placed in
a vial with 1 ml of PBS. The vials were then placed in a 37C water bath and covered in foil.
Periodically, the vials would be removed from the water bath, buffer pipetted out into
Eppendorf™ tubes (for future dug concentration testing via High Pressure Liquid
Chromatography (HPLC/UV-Vis (Section 3.2.2.1)) and 1 ml of fresh buffer added to the vials.
The vials were then returned to the water bath.
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Drug release was then tested according to Section 3.2.1.3 & 3.2.1.4.
3.2.1.2 Drop cast samples
In order to create samples ready for weighing, a scalpel was used to cut 7 mm x 7 mm
squares from the polymer sheets. Samples were taken from the centre of the sheet to
minimise the variation in thickness. These too were placed in a 1ml vial of PBS and followed
the same protocol as 3.2.1.1.
3.2.1.3 Short-term testing via HPLC/UV-Vis:
For DEX scaffolds, and the testing of burst release, samples were taken after 1, 2, 4, 8, and
24 hours. Following this, samples were only taken once every 24 hours until it was deemed
no more testing was necessary. The maximum duration of short-term testing was 2 weeks.
3.2.1.4 Long-term testing via HPLC/UV-Vis:
One of the project aims is to create an implant capable of steady release of Phenytoin over
the period of a year. Unfortunately, due to the short time frame of the project, this is not
practicable. Past assays have shown (Zolnik, Leary, & Burgess, 2006) that elevating the
temperature of the water bath by 10 C triples the drug release rate. The original intention
was to raise the water temperature to over 60°C, thereby being able to replicate a year’s
release within a single month. However, due to the low melting point of PCL/glass transition
temperature of DL-PLA, the bath was only able to be set at 50°C. Although complete release
was not able to be achieved, the desired release profile was still able to be established. Unlike
with short term release, samples were only taken every two days. The difference in
methodology is due to a difference in temperature. Burst release is dependent on
temperature, and any burst release measured at elevated temperatures would not accurately
represent the burst release which would be seen at body temperature. There is also a
difference in the profile as the DL-PLA mix is intended to create a zero-order release profile
(Section 1.3.2), i.e. a linear release profile. As such, fewer samples are required to accurately
portray the profile.
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3.2.2

Drug release analysis

3.2.2.1 Reverse Phase HPLC
For the purposes of this project, the Agilent HPLC 1260 Quaternary system was used with
a Gracesmart RP 185u column. Temperature was set to 40°C and standard flow rate set to 1
ml/min with a mobile phase of acetonitrile and water. Before sample analysis, standard
curves are required to determine concentrations. A 1 mg/ml solution was created of
drug/ethanol. 100 µl was removed and added to an Eppendorf tube with 1900 µl of PBS. After
mixing well, 1 ml of solution was removed and added to another tube and topped up with 1
ml of PBS. This was repeated until 10 standards were created. Given the hydrophobicity of
the drugs, ethanol is required as an initial solvent.
Although, there are a variety of possible methods which can be used for the separation of
DEX and PHT, after multiple tests, a one-step mobile phase of a mixture of Acetonitrile and
water was deemed most suitable. The acetonitrile/water ratio was determined for each drug.
Less acetonitrile resulted in longer elution times and wider peaks. However, it also allowed
for clear separation of peaks, which was necessary when multiple drugs were in solution. The
buffer itself (PBS) also resulted in an early peak, which set a lower boundary for elution time.
A method was developed which defined flow rate, temperature, ratio, run duration and
wavelength. Run duration is important as it must allow for all products to flow through the
column before a new sample is injected. Wavelength is set such that there is a maximum
response for a specific compound. Each standard was run, integrated to find peak area, and
the corresponding concentration appended. All samples were plotted, and a linear line of best
fit was created. This curve was then added to the earlier method.
Following calibration, samples were filtered into vials using a 0.22 μm syringe filter. A
sequence was created with all samples, defining the number of samples to be taken per vial,
and method to be used. The amended method with attached calibration curve was used
rather than the original. This allows us to automatically detect which peaks we wish to
integrate and know the concentration of a sample given the peak area. All samples were run
as a batch, and afterwards integrated. The program allows one to export a summary table of
sample name and corresponding concentration.
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These were then imported into Microsoft Excel and applied to the following equations:
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^ This is equal to the concentration as we used 1 ml aliquots.
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In order to determine the accumulated release, we add the sample mass to the previous
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Following this we found the average of the samples (3-4 runs per sample) and determined
the standard error. These were then plotted on a graph against the corresponding time at
which the aliquot was removed.
3.2.2.2 UV-Vis Spectroscopy
A Shimadzu UV-Vis system was used as an alternative to the HPLC during times when the
Agilent system was unavailable. The benefits to such a system were the increased speed per
individual sample and the lack of filtration required. However, each sample was run manually,
with cleaning of cuvettes required between each sample. Plastic cuvettes are not an option
for the measurement of absorption in the UV spectrum. Furthermore, unlike with HPLC/UVVis wherein separation of compounds occurs before measurement, all compounds are
measured at the same time which is problematic if all/multiple compounds have a response
at the target wavelength. As such, only single compound samples are suitable for
measurement. Calibration was similar to Section 2.3.5.1; however, instead of vials, the
samples were put straight into quartz cuvettes. Cuvettes come in pairs with identical
refraction coefficients. One is filled with pure buffer solution, and the other with sample. The
absorption value for the pure solution is subtracted from that of the sample solution. Before
a new sample is tested, the cuvette must be rinsed 3 times in ethanol and dried thoroughly.
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In addition, as mentioned above, sample time is almost instantaneous as there is no
separation of compounds required.
3.2.3

Comparison of drop cast films and printed structures

A polymer sheet of Dex loaded PCL was created via drop cast evaporation (Section 2.2.1). 7
mm x 7 mm samples were taken from the centre of the sheet after which the sheet was sliced,
fed into the bioplotter and melted. The height of the drop cast samples was measured using
optical profilometry and an STL model was created for a solid printed sheet and an open
scaffold at the same height (347.5 µm ± 22.5), after which the polymer was extruded and
height was measured. Using the printed PCL polymer samples, HPLC was used to measure the
% DEX release over a period of 120 hrs. Figure 23 shows a visual comparison of the three
forms of sheet: Solid Printed (left column), drop-cast (middle column), and open scaffold
(right column). The first row highlights the difference in surface texture via stereo microscope,
with the middle and bottom row show the use of optical profilometry to highlight the
difference in height.

Figure 18: Comparison of drop cast and printed structures |
Top: Stereo Microscope image of Printed Sheet (A), Drop Cast Sheet (B) and Printed Lattice (C). Notes:
Magnification not noted. (B) exhibits rough surface at higher magnification.
Middle: Optical profilometry-false colour images with colour corresponding to height for Printed Sheet (D),
Drop Cast Sheet (E) and Printed lattice (F). Blue=glass plate (min height), Green=middle layer, Red=top layer
(max height). Notes: (D) and (E) imaged at edge of print structure, (F) in centre.
Bottom: Cross sectional height profiles for Printed Sheet (G), Drop Cast Sheet (H) and Printed Lattice (I).
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3.2.4

Scaffold Morphology & Polymer Variation

3.2.4.1 Open vs. Closed Scaffolds
Scaffold fabrication followed the procedure defined in Section 2.2.2.1.1 with scaffolds
comprising of 4 printed layers, differing only in whether they were open or closed. Using
these printed scaffolds, HPLC was used to measure % DEX release over a period of 148 hrs.
3.2.4.2 Pore Size/Grid Spacing
Different models were created in which the grid spacing differed with values of 1 mm, 0.8
mm and 0.6 mm. Grid spacing as defined by the software was compared to actual grid
spacing (distance between row centres) to verify that the computer measurements
accurately reflected real-life measurements. Nevertheless, when considering pore size, it is
necessary to consider the actual row width. As stated in Section 2.2.2.1.2, this is difficult to
set and is dependent on many factors. As such, the grid spacing as set in the programming
was used. Scaffold fabrication followed the methodology in Section 2.2.2.1.1. Triplicate of
3-layer scaffolds with grid spacings of 0.6, 0.8, and 1.0 mm were printed and analysed, with
release measured over 278 hours.
3.2.4.3 Layer Number/Scaffold height
Models were created with a number of layers varying from 3 to 8 layers. Unfortunately, an
issue presented itself within the 4-layer samples, and as such, they were removed from the
test. The intention was to test the effect of layer height/number on drug release. Scaffold
fabrication followed the methodology in Section 2.2.2.1.1; printing triplicate scaffolds with
3, 5, 6, 7 and 8 layers. These were then analysed with release measured over 122 hrs.
3.2.5

Drug & Polymer Variation

3.2.5.1 Drug Comparison: Dexamethasone vs. Phenytoin
Dexamethasone and Phenytoin loaded PCL scaffolds were created in order to establish
whether drug type could influence drug release. Scaffolds were prepared as per Section
2.3.1. Excepting drug type, properties (size, grid spacing) were kept constant throughout at
7 mm and 600 μm respectively. Aliquots were taken over 72 h and the drug release was
analysed via HPLC.
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3.2.5.2 Polymer Comparison: PCL vs. DL-PLA
Protocol followed that of Section 3.2.5.1, however, rather than vary the loaded drug, PHT
was loaded into both PCL and DL-PLA before they were both printed. Polymer preparation
and printer properties followed the methodology laid out in Section 2.2.2.1.1 for PHTloaded PCL polymer and Section 3.2.5.2.1 for PHT-loaded DL-PLA.
3.2.5.2.1

Preparation of PHT-loaded DL-PLA scaffolds

2 g of PHT-loaded Dl-PLA was created via drop-cast evaporation (Section 2.2.1.1.2). The
method for removal of PLA from the petri dishes differs from that of PCL (Section 2.2.2.1.1).
Unlike PCL, DL-PLA is a non-crystalline polymer and is elastic at room temperature. As such,
it is difficult to cut the polymer sheet into strips. Instead, sections of the sheet are placed and
compressed in the extrusion tube. Non-crystalline polymers do not have a melting point, but
rather transition from solid to gel as temperature increases. Although the glass transition
temperature of DL-PLA is ~60°C, the printer temperature was required to be set at 170°C in
order to aid extrusion. Furthermore, due to the gel-like nature of the polymer, a larger tip (27
g) was attached. As with PCL, the extrusion pressure was set at 500 kPa, however, there was
often variance in the temperature, pressure, and feed rate (100-150 mm/min) required for
optimum printing.
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3.3 RESULTS & DISCUSSION
3.3.1

Comparison of drop cast films and printed structures

Drug-loaded films are commonly used for preliminary drug release testing and are most
often created via drop-cast evaporation due to the simplicity of the method and minimisation
of material wastage. 3D printing has been considered as an alternative due to its ability to
create tailored, reproducible samples. However, noted problems include lack of uniformity
and difficulty in controlling thickness. Before experimenting with various printing parameters,
it was necessary to see whether the variation in methodology created variation in drug
release profile.
Using the printed PCL polymer samples above, HPLC was used to measure the % DEX
release over a period of 120 hrs (Fig. 26). The release profiles demonstrate little variation
between drop-cast (orange trace) and full printed sheets (yellow trace). A slight deviation
between the two may be due to the greater density of the drop cast samples (Av=1.17 g/cm)
as opposed to the printed sheets (Av-0.94 g/cm). With regards to the open scaffold (green
trace), a more porous scaffold can account for the quicker release and overall increase of 
10 -20 % in drug release. This will be further demonstrated in Section 3.3.2.2 To our
knowledge, this is the first report of a drug release profile of a 3D printed scaffold compared
to that of a drop-cast film. A general finding is that the processes of printing (e.g. melt and
extrusion of the polymer through the needle) do not significantly affect the drug release
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Figure 19: Drop cast, full sheet, scaffold release profile comparison at constant height (~350um)
of DEX-loaded PCL | n=3, t=120h, temp=37°C, error bars not visible
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profile (i.e. printed sheet versus drop-cast) although as expected the structure of the end
product (i.e. lattice) will have an effect.
3.3.2

Scaffold Morphology & Property Variation

3.3.2.1 Open vs Closed Scaffolds
It was hypothesized that there would be a difference in the release profiles of closed and
open scaffolds, i.e. that the links between rows would contribute to burst release. (Fig. 27).
The left side of figure 27A shows the printed scaffold with only a single printed layer, in which
we can clearly discern the open (bottom left) and closed (top left) structure, with the right
side of the figure demonstrating the lattice structure after the addition of a second layer. Drug
release measurements showed that there was no statistical difference between open and
closed scaffold systems (Fig. 29B). Assuming uniform thickness along links and rows, the
closed scaffolds contain 11% more polymer per sample than the open scaffolds (calculated by
volume of cylindrical/toroidal shapes). This is well within the variance of sample weight, so it
is unsurprising that the addition of row links does not contribute substantially to a difference
in release profile. Lowering the corner acceleration value could possibly lead to a greater
difference in profile due to greater polymer deposition along the links, but present results
appear to show that this parameter does not contribute greatly to the release profile of the
scaffold.
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Figure 20 (A). Stereomicroscope images of open vs. closed Scaffolds | Top: Closed, Bottom: Open, Left: Single layer, Right:
Multi-layer. (B)Effect of Open vs Closed Scaffold design on release profile of DEX-loaded PCL scaffolds | 4 layer, n=3, t=148h,
temp=37°C, error bars=not viewable
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3.3.2.2 Pore size/grid spacing
Porosity is a well-known contributing factor in the determination of a release profile. It
allows for the variation in scaffold mass without change in scaffold size and determines the
amount of liquid present in the scaffold. As diffusion often plays a major role in the control of
drug release, the amount of liquid present is strongly correlated to release rate. Often
porosity is considered on a micro-scale and in films is affected by the method of polymer
synthesis (Higuchi, 1962). In this assay, the focus was on macro-scale pore size. The intention
was to determine whether or not a change in pore size would affect the drug release rate.
Figure 28A highlights the difference between software-defined grid spacing and that of the
measured grid spacing, with results verifying that the computer measurements accurately
reflect their real life counterparts, with a variation of less than 2% maximum. In Figure 28B, it
is demonstrated that release rate is directly proportional to grid spacing, with each increase
in grid spacing of 0.2 mm resulting in an increase in total percentage release (at t=278 h) of
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Figure 21: (A) Stereoscopic images of single layer close PCL scaffolds with variation in grid spacing from 0.6 to 1.0 mm | L:
1.0mm, M: 0.8mm, R: 0.6mm (B)Effect of grid spacing variance in Dex-loaded PCL scaffolds on drug release profiles | n=3,
t=278h, temp=37°C
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~5%. However, between t=100 to t=278, release between all samples occurred at the same
(and constant)) rate. Comparison with other research (Schnieders, Gbureck, Vorndran,
Schossig, & Kissel, 2011) supports the theory that an increase in porosity results in an increase
in burst release and, consequently, faster total release. However, it must be stressed that the
total mass of drug in the scaffolds with larger pore size (1.0 mm) is less than that of those with
a smaller pore size (0.8 mm and 0.6 mm) and that, in fact, according to mass, the increase in
porosity results in lower release per unit time (see Figure 29). To see whether grid spacing is
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Figure 22: Grid spacing (mass) |n=3, t=278h,
temp=37°C

in fact a factor in drug release rate, we must keep all other parameters: drug mass and drug
concentration, as constant, which in fact corresponds to a constant volume. Although the
KIMM bioplotter lacks the ability to track volume dispersed, we attempt to look at this in
Section 5.3.4, wherein we look at surface area per unit volume.
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3.3.2.3 Number of layers/scaffold height
Scaffold height/layer number affects not only the total amount of drug present but also
the surface area to volume ratio. An increase in size results in a decreased ratio, which in turn,
can affect the release rate (see Section 5.3.4). It was observed early on that it was difficult to
correlate layer number to scaffold height. As such, any mathematical modelling would require
two separate models: ‘scaffold height vs release’ and ‘layer number vs release’. Furthermore,
at the time of printing, there was an issue with the print bed height resulting in large variation
in print height. In order to accurately mathematically model number of layers vs. release,
more samples would have to be created with a smaller variation in height.
Results (Fig 32A) show a correlation between an increase in number of layer and a decrease
in the rate at which the drug is released. Studies using DEX21P-loaded PVA (Rattanakit et al.,
2012) present similar findings in which 40% of the drug in the 1-layer system was released
over the first 14 days, whereas the 2 and 3-layer systems released 31% and 22% respectively
within the same time frame.
A preliminary analysis of sample height vs release at 72 hours was completed (Fig 32B) and
appears to demonstrate a linear relationship. The original intention was to compare it with a
previous model (Lao, Venkatraman, & Peppas, 2008), however, the number of samples taken
was below that required for an accurate comparison. Furthermore, the presented model
doesn’t take into account grid spacing, and, as such, would not be appropriate for these tests.
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Figure 23: Effect of Layer Number and Scaffold Height on release rate of DEX-loaded PCL
(A) Effect of layer number on release profile for DEX-loaded PCL | 3-8 layer, n=3, temp=37°C, t=122 h
(B) Effect of scaffold height on release rate of DEX-loaded PCL: drug released @72 h |n=1, temp=37°C
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3.3.3

Drug & Polymer Variation

3.3.3.1 Drug comparison: Dexamethasone vs Phenytoin
Dexamethasone and Phenytoin loaded PCL scaffolds were created in order to establish
whether drug type could influence drug release. Scaffolds were prepared as per Section
2.2.2.1.1. Excepting drug type, properties (size, grid spacing) were kept constant throughout
at 7 mm and 600 μm respectively. Both PCL graphs (Fig. 33) display similar type of release
profile, however, the % release of phenytoin (orange trace) was significantly lower than that
of the Dexamethasone (blue trace) loaded samples. This is due, perhaps, to the greater
hydrophobicity of PHT over DEX (log P of 2.47 vs 1.83) (Hansch, Leo, & Hoekman, 1996).
However, this is speculative, given the number of differences in the chemical properties of
the two drugs. (Li et al., 2007) demonstrated a similar release profile with PHT microspheres
of PCL with rapid release within the first few days followed by slower, controlled release for
the next 8 days, ending with a slow, controlled release continuing until the end of the study
at 3 weeks. However, unlike the wok of Li et al. the release here is more rapid but it does
appear to follow the same triphasic release.
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Figure 24: Drug release comparison of PCL+DEX, PCL+PHT, and PLA+PHT | n=3, t=72 h
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3.3.3.2 Polymer comparison: PCL vs DL-PLA
A comparison between PCL and PLA scaffolds, was required to verify that polymer type can
have an effect on release rate and type. Scaffolds were created using the methodology
presented in Section 3.3.3.1, however, printing was configured such that the only contributing
variable was polymer type. Figure 33 demonstrates that use of the PLA scaffold contributes
to a much slower release rate (of the PHT, grey trace in Fig. 33) compared to that of the PCL.
Given the need for long term release, this supports our use of PLA with Phenytoin. Figure 34
shows the same PHT-PLA data (rescaled) that demonstrates burst release within the first 20
hours, followed by the slower release up to 80 hrs. In the short time frame over which this
was tested, we were unable to determine whether the PLA/PHT system resulted in zero-order
release. Subsequent tests over longer periods (see Section 4.2.3.1) investigated this further.
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Figure 25: Release profile of PHT-loaded PLA| n=3, t=72h, temp=37C
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3.4 CONCLUSION
In this chapter, it was demonstrated that printed drug-loaded sheets exhibit similar release
profiles to those created via drop-cast evaporation. Having achieve this, we were then
required to look at the effect of scaffold morphology e.g. pore size, on the release rate of
our drugs. Open scaffolds (see Section 3.3.2.1) showed no difference in release rate when
compared to that of closed scaffolds. On the other hand, by altering the pore size (see
Section 3.3.2.2) and layer number (see Section 3.3.2.3), we can greatly alter the release rate.
Specifically, an increase in pore size results in a faster release rate, whereas an increase in
scaffold height/layer number, produced a slower release rate. However, this is only taking
into account percentage release rate, and when considering total release rate (mass), a
greater grid spacing actually produces a slower rate of release. Future experiments may also
take into account the volume, through density measurements.
In addition, a comparison was made between Dexamethasone and Phenytoin, in order to
test the effect of drug type on release profile/rate of release. It was determined that while
both drugs appear to have similar release profiles, the DEX released at a much faster rate
than that of the PHT, which is preferential for our goal: the quick release of DEX coupled
with the slow, sustained release of PHT over a year.
Finally, a comparison was made between PCL and DL-PLA, in which it was shown that the
use of DL-PLA results in a greatly slower release rate in contrast to the PCL. Of all
parameters tested in this chapter, the choice of polymer resulted in the largest variation in
release rate. As such, it appears that the use of PHT-loaded DL-PLA coupled with DEX-loaded
PCL, is the preferential combination for creating our dual release implant.
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4. EXPERIMENTAL: EFFECT OF 3D PRINTED CORE-SHELL STRUCTURE ON
DRUG RELEASE
4.1 INTRODUCTION
4.1.1

Background

Dual- or multi-controlled drug delivery systems has been the goal of labs for decades now.
In 1996, a paper was published highlighting the simultaneous release of levonorgestrel and
estradiol within a polymer matrix laminate system (PCL and DL-PLA)(Ye & Chien, 1996).
Since then, and with the advent of 3D printing which allows for greater tailoring of DDS
shape, a large number of implants and tablets have been created which attempt to use the
unique properties of the polymers, drugs, and printed structure to produce multiple release
profiles from a single system (Prasad & Smyth, 2016). The drugs used varied greatly, from
immunosuppressants such as Zotarolimus (Tarcha et al., 2007) to antibacterials like
Levofloxacin (Weigang, Qixin, Xiaodong, & Weidong, 2009), to lipid lowering compounds
such Pravastatin (Khaled, Burley, Alexander, Yang, & Roberts, 2015). The latter was a five-inone tablet which was able to show sustained release for three drugs over 720 hours
(Pravastatin, atenolol, Ramipril) and immediate release for the two others (Aspirin,
Hydrochlorothiazide). However, as of 2018, no implant or tablet has been produced which
provides dual release for an antiepileptic such as Phenytoin with another drug.
4.1.2

Objective

The last stage of this project focuses on the creation of complex drug release systems. For
this investigative project, it was decided to focus on a primitive core/shell structure, wherein
the PLA/PHT scaffold would be placed within a PCL/DEX box. Despite the simplicity of the
structure, there are numerous variations which could be created, which, in turn, could create
unique drug release profiles. Given the time constraints it was decided to focus on shell
porosity, thickness and shape, as well as core concentration.
Given that the PLA scaffold demonstrated a burst release, it was necessary to see whether
the shell would minimise this release. By varying the porosity of the shell, we are able to
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define the shape of the PHT release profile. The next step involves setting the rate of PHT
release, by altering the thickness of the shell. There are two issues that need to be resolved
before we can create a finished product: 1) a block structure may not be the most
suitable/effective structure for implantation in the brain, 2) Every individual requires a
different dosage and it would not necessarily be appropriate to scale the implant accordingly.
The first issue can be addressed by analysing various other shell shapes. Can we produce a
similar release profile with a variety of shapes? The second is more simple and can be applied
to both the core and shell: variation in drug concentration. By analysing these four factors,
we can create an implant tailorable to any individual.
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4.2 METHODS
Excepting Section 4.2.2 (short term release), all experiments in Chapter 4 require long term
release studies and follow the protocol laid out in Section 3.2.1.4. In order to improve HPLC
separation and improve ability to accurately measure small concentrations, HPLC settings
were adjusted to 30% acetonitrile, and 30 µg draw per sample.
4.2.1

Preparation of DEX-loaded Printed Shell Structures

The methodology was similar to that in Section 2.2.2.1.1, however, the .stl file was required
to be created externally using Dassault Systèmes Solidworks 2015 and then imported into the
Bioplotter software. The Bioplotter software, whilst able to make simple solid structures such
as blocks and cylinders, lacks the ability to create complex structures. There are two separate
structures created. Firstly, an open box structure of inner dimensions 6x6x0.7 mm. Outer
dimensions are dependent on thickness of walls (0.5, 1.0, 1.5 mm) (Figs 35A and B). Then a
PLA scaffold described in Section 2.3.2 is placed in the PCL box (Figs. 35A). The PLA scaffolds
were of size 4x4x0.5 mm, leaving room for placement in the PCL open box. Finally, a lid is
attached to the top of the open box with heat (Figs. 36A-C). Attempts to print the lid on top
of the placed PLA scaffold were unsuccessful and produced inconsistent samples. The lid is
attached via fusion of the outside edges to the base using a soldering iron set at 100°C.

0.7 mm

22 mm

DL-PLA (core)

6 mm

PCL (shell)

16-36 mm

PCL (shell)

Figure 26: Cross-section of PCL box | A: Solidworks diagram B: Stereomicroscope image

Figure 27: Creating a shell structure |A: PCL scaffold placed in open box | B: Lid is place on box | C: Lid and base are
attached
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4.2.2

Effect of shell on burst release

Shell/core structures were created according to the process detailed in Section 4.2.1. In
this assay, grid spacing was set to 0.2 mm and 0.6 mm for solid (Fig. 37A) and porous shells
(Fig. 37B) respectively. Four samples of each structure were placed in water baths for 7 days
alongside pure PLA/PHT scaffolds for comparison (Section 3.2.1.3) (Fig. 37C).

Figure 28:Stereomicroscope image of Full vs Porous PCL Shell | PLA core scaffold

4.2.3

Long term release profile of Phenytoin

It has been observed (Kunou et al., 2000) that a mixture of high and low molecular weight
DL-PLA at a ratio of 4:1, would produce a zero-order release profile. The lab was unable to
secure the specific molecular weights used in the previous assay (70 k/130 k:5 k). Instead,
DL-PLA polymers of 2.0 dl/g and 0.4 dl/g were used (molecular weights cannot be calculated
directly but are rather derived from a correlation with the inherent viscosity). The respective
molecular weights are ~450 k and ~25 k. It was, as such, necessary to test whether altering
the polymer MWs would affect the release profile. Sample creation and release preparation
followed methodology in Section 2.2.1.1.2 & Section 3.2.1.4, wherein samples were placed in
hot water baths at 50°C for 10 days.
4.2.4

Effect of shell thickness

PCL shells of thickness 10 mm and 15 mm (Figure 39 A & B) were printed and a PLA core
scaffold was placed within it as described in Section 4.2.1. The porosity present in these shells
was a consequence of ill-tuned external parameters, namely tip height and layer height. The
rows in lower layers melded together, however, as the number of layers increased, the fibre
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width decreased, creating pockets. Drug release rate was compared with that of PLA core
scaffolds without shell at elevated temperature (50°C), simulating long term drug release.

Figure 29: Stereomicroscope images of (A) 10mm and (B) 15mm thick cube.

4.2.5

Effect of shape: cylinder vs cube

5 mm box scaffolds (Fig. 41A) were printed and compared with equivalent cylindrical
shaped scaffolds of equal volume (Fig 41B).

Figure 30: Stereomicroscope images of a) 5mm box scaffold b) equivalent volume cylinder
scaffold

4.2.6

Effect of core drug concentration

Scaffolds were created following the methodology followed outlined in Section 4.2.1,
however, initial polymer synthesis of the PHT-loaded PLA varied in its doping concentration,
with concentrations of 4% and 6% PHT being added to the initial drug-polymer blend.
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4.3 RESULTS & DISCUSSION
4.3.1

Effect of shell on burst release

DL-PLA composite, whilst showing zero order release in the long term, tends to show burst
release early on. This has been demonstrated in Section 3.3.3.2 and in other studies (Kunou
et al., 2000). Unfortunately, as stated in Section 1.1.5.1, Phenytoin has a very narrow
therapeutic range and there’s a fine balance between ineffective and toxic. A burst release
may result in a toxic quantity of drug being injected into the system. As such, it is necessary
that we try and minimise this burst release as much as possible. It was hypothesised that this
could be solved by use of a shell structure.
Due to the inability to separate Phenytoin and PCL peaks during HPLC, the data for shell
(full and porous) samples was unable to be extracted. Future studies would require the use
of a higher concentration of Phenytoin. Despite this, it was able to be shown (Fig. 44) that,
following a short burst release within the first 6 hours, the PLA composite produces a zeroorder release profile. Due to the short testing time, this was unable to be definitively
demonstrated in 3.3.3 and, as such, was required to be reassessed here. As stated previously,
this is appropriate for the long-term release of Phenytoin. Although unable to be verified in
this study, other studies (S.-H. Lee, Baek, Kim, & Choi, 2009) have indeed shown that use of a
core-shell structure does, in fact, minimise burst release.

Burst Release Analysis
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Figure 32: Burst release analysis of PHT-loaded PLA without shell | t=180h, temp=37°C, n=3
Notes: Burst release present from t=0 to t=6h. From t=6h, zero order release is exhibited.
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4.3.2

Long term release profile of Phenytoin

It is demonstrated in Fig. 44 that the polymer DL-PLA core scaffold does in fact result in a
zero-order release profile and maintains it for an extended period. The Arrhenius equation is
used to determine whether drug release trials at elevated temperatures can be used to
predict ‘real time release’:
=

/

∗

(eq. 5)

Where k=zero order release rate, Ea=activation energy, R=gas constant, T=Absolute
temperature. The Ea is dependent on the molecular weight of the polymer (cite), stirring rate,
and pH, and as such is difficult to establish, especially in a polymer mixture. In particular, as

PHEN in DL-PLA
60

Drug Released (%)

50

y = 5.3726x - 6.1585
R² = 0.9909

40
30

PHEN in DL-PLA

20

Linear (PHEN in DLPLA )

10
0
0

2

4

6

8

10

12

Days
Figure 33: Long Term Drug Release of PHEN loaded DL-PLA | t=10 days, temp=50C, n=3

the molecular weight increases, the Ea decreases. As such, a lower MW polymer profile will
be affected more by a temperature shift as opposed to a higher MW polymer. However, it
must also be noted that the value of A in the Arrhenius equation is proportional to the
molecular weight i.e. higher molecular weight=slower release. This is demonstrated by Kunou
et al. in which 50% release of the 70 k/5 k polymer mixture occurs at ~75 d, whereas 50%
release of the 130 k/5 k mixture occurs at ~120 d, with total release occurring at 200 d and
260 d, respectively. From this, we can assume that the ~450 k DL-PLA will produce zero-order
release over greater than 12 months. If a) we extrapolate from the linear data represented in
Figure 44, and b) approximate zero-order release for the duration of release (which appears
appropriate given the data in Figure 46), estimated total release of Phenytoin in DL-PLA
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blended scaffold will take place after approximately 430 days. This is ideal for our intended
function, and, as can be seen in Section 4.3.3, the use of a shell would further retard the
release of the anti-epileptic.
It should be reiterated that at elevated temperatures we are unable to accurately predict
the “real-time” burst release phase due to an increase in polymer mobility (increasing drug
release via diffusion) and surface morphology changes (decrease in drug release). As such,
‘real time’ studies i.e. at 37°C (Section 4.3.1) were also performed.
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4.3.3

Effect of shell thickness

It was theorised that a thicker PCL shell structure would further inhibit the release of the
Phenytoin from the DL-PLA core scaffold. Furthermore, it presents the opportunity to increase
the dosage of Dexamethasone (if required). In this and the following chapters, DEX release
was not measured. After creating an ideal PHT release profile, targeted DEX release can be
achieved by following the protocols examined in Chapter 3.
Figure 47 appear to confirm the theory that use of a shell greatly inhibits the release of the
core drug; the effect of which is exaggerated as the shell thickness is increased. However, the
exact nature of the relationship between shell thickness and release rate was not established.
This agrees with past studies (Xia, Ribeiro, & Pack, 2013) where double-walled microspheres
(BSA-doped PLGA core with a non-doped PDLA shell) were tested for the effects of shell
thickness on drug release, with results demonstrating greater delay of drug release with
greater wall thickness.
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Figure 34: Release profile comparison of a PHT-loaded PLA core scaffold w/o (grey) and w/
10mm (orange) and 15mm (blue) shells |n=3, temp=50°C, t=10 days
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4.3.4

Effect of shape: cylinder vs cube

Although the end goal of this research is the creation of a brain implant, it is quite unknown
what is required of the implant, including placement, shape and size. Recent studies
(Goyanes, Robles Martinez, Buanz, Basit, & Gaisford, 2015) have showed that shape does
indeed have a large effect on the release profile of the loaded drug. A similar sized sample
may have either a) a different mass b) a different volume c) a different surface area, all of
which may affect the release rate.
It was decided to compare the 5 mm box scaffold (Fig. 41A) with an equivalent cylinder
scaffold of equal volume (Fig 41B). (Goyanes, 2015) analysed the effect of altering implant
shape on drug dissolution profile. A variety of shapes were tested including cylinders and
cubes. In their analysis, they found that for a constant weight (volume), the release rate of
the cylinder samples was faster than that of the cube samples. The greater the surface area
to volume ratio, the greater the diffusion rate. In this assay, cuboid implants exhibited a SA:V
ratio of 1.747 , whereas the cylinders exhibited a SA:V ratio of 1.68. The model suggests that
the samples should produce highly similar release rates, with the cuboid releasing at a slightly
faster rate. This is supported by our results, as shown in Figure. 48.
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Figure 35: Effect of shell shape (Cylinder vs Box) on the release profile of Phenytoin in box system| t=10 days, temp=50°C, n=3
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4.3.5

Effect of core drug concentration

Although drug concentration is not defined within the scope of this project, as it does not
relate to the intrinsic physical properties of the scaffold, it is of central importance in trying
to create an implant tailored to every individual. In altering the drug concentration, we can
change the release profile (total and percentage released) without redesigning the implant
itself. Methodology followed that outlined in Section 2.2.1.1.2, however initial polymer
synthesis of the PHT-loaded PLA varied in its doping concentration.
The results in Fig. 49 appear to contradict established views on the subject of drug loading
and release rate (Mishra, 2015) which stipulate that a high drug to polymer ratio correlates
to a high release rate. Further studies must be undertaken in order to determine whether this
difference is a unique attribute of the specific system or whether there is a fault in the
methodology.
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Figure 36: Effect of core drug concentration (4% vs 6% Phenytoin in PLA) on the release profile of
Phenytoin in box system| t=10 days, temp=50°C, n=3
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4.4 CONCLUSION
In this chapter, we tested the viability of creating a core-shell polymer structure, allowing
for the simultaneous release of both Dexamethasone and Phenytoin whilst allowing each
drug to have their own unique release profile. Our first test focused on minimising the initial
burst release of Phenytoin, a problem given Phenytoin’s narrow therapeutic range. Issues in
the testing methodology resulted in a difficulty to extract data (see Section 5.3.1), however,
past research has indeed shown that use of a core-shell structure minimised burst release.
The next stage involved the analysis of long-term release of Phenytoin. We were able to
successfully simulate this over a shortened period of 10 days by increasing the surrounding
temperature to 50℃. Extrapolation of results predicted a zero-order release for the
duration of the release period with total release occurring after 430 days.
Following this, the physical shell properties were altered: first, by changing the shell
thickness, and second, by changing the shape of the shell. It was able to be shown that a)
use of a shell structure greatly inhibits PHEN release from the internal scaffold b) the release
retardation is directly proportional to the thickness of the surrounding shell. As such,
through only varying the shell thickness we can set the total release time of the internal
drug, perhaps set to coincide with a yearly hospital check-in. The change in shell shape, on
the other hand, was necessary in the case that a box implant, either due to size or shape,
was not appropriate for subdural implantation. Past research has shown that diffusion rate
is proportional to Surface Area to Volume ration. By creating a cylinder with a similar ratio,
we were able to produce a release profile very similar that of the box, but without the
possible issue associated with the box’s sharp edges.
The final assay was a quick analysis of the effect of core drug concentration on release
profile. This analysis was not in depth and, at initial glance, appears to contradict past
research that demonstrates that higher drug concentration results in a faster release rate.
Further testing is necessary in order to verify our results.
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5. GENERAL CONCLUSION
The project revolves around the construction of 3D printed drug delivery systems
engineered to produce complex and tailored drug release profiles for multiple drugs; in
particular, a slow release anti-epileptic (Phenytoin) and a quick release anti-inflammatory
(Dexamethasone). This preliminary research was intended as a feasibility study.
In Chapters 2, practical considerations required when 3D printing drug delivery systems
were investigated. Section 2.3.2 analyses the effect of external printer parameters, namely
feed rate and temperature, on the final product. It highlights the importance of initial material
choice and the need to optimise these parameters at the outset in order to ensure uniform
products. It was demonstrated that an increase in temperature results in increased polymer
fluidity, and consequently, thicker row width. The same effect can also be obtained by slowing
the feed rate (horizontal axes speed). Both these relationships were found to be linear.
Section 2.3.2.4 stresses the importance of reproducibility in analysing the practicability of
using 3D printing. Present research shows variation in product and this will need to be
resolved before further research can be undertaken. An additional factor must be considered,
that of the effect of printing at high temperatures on the nature of the loaded drugs. Section
2.3.3 looks at the effect of temperature on two drugs, DEX and PHEN, with initial analysis via
NMR and FTIR showing no apparent change in the chemical structure of the drugs. Chapter
3 manages to show that it is indeed practicable to use 3D printing for the creation of a drugloaded polymer implant and highlights optimal procedures for polymer creation and scaffold
printing.
Having successfully managed to print a scaffold in Chapter 2, Chapter 3 looks at the effect
of altering drug, polymer, and scaffold parameters on the release profile of drug-loaded
scaffolds, with the intention of establishing which are the most influential parameters. In
order to successfully analyse our results, we need to be able to compare it with past research.
This is difficult given the little research that has been done into 3D printing DDSs. However,
we can use results from other DDSs assuming that the act of 3D printing does not change the
inherent shape of the release profile. Section 3.3.1 compares sheets of printed and drop-cast
drug-loaded polymer with little difference being seen between the two sample sets.
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This being established, Section 3.3.2 looks at the effect of altering scaffold parameters:
open vs closed, grid spacing, and number of layers. No detectable difference was noted
between open and closed scaffolds, however both grid spacing and layer number/height
appeared to have a significant effect on release rate, with an increase in pore size resulting in
a faster release rate and an increase in scaffold height/layer number producing a slower
release rate. In these cases, however, special care must be taken when considering whether
total drug release or percentage drug release is the most important factor, as this can greatly
influence the choice of parameter value. Section 3.4 looks at the intrinsic materials of the
drug-loaded polymer, contrasting the drug release profile of two drugs, DEX and PHT: the
required drugs for our final implant, and PCL and DL-PLA: two suitable polymers for use in our
implant. The release pattern of both our drugs exhibited similar profiles, however the DEX
released a lot quicker than the PHT, preferential given our need for quick release of DEX and
slow, sustained release of PHT. Looking at the effect of polymer type on release rate, DL-PLA
scaffolds released at a much slower rate than that seen with PCL. Of all parameters tested in
both Chapter 2 and Chapter 3, this was the most influential in determining release rate and
profile shape.
Given what we learnt in previous chapters, Chapter 4 sets out to design a complex dualrelease polymer implant. Building on past research and the above results, core-shell
structures were created with a PHT-loaded DL-PLA core scaffold, surrounded by a shell of
DEX-loaded PCL. Previous tests had only analysed drug release over a short period of time,
however, in order to ensure that the loaded PHT released at a constant rate over a period of
greater than a year, further tests were required. Given the short time frame of the project,
and the difficulty of ensuring an uninterrupted test over a year, the drug release was
accelerated through increasing the surrounding temperature. It was able to be shown that,
barring an initial burst release (minimised through use of a shell), the release profile was zeroorder and total release time was greater than 12 months. Having satisfied the ability to
release our primary drug over an appropriate time period, it was now necessary to consider
the new factor in play: the PCL shell. Use of a shell structure greatly reduced the rate at which
the PHT was released, with retardation increasing with the use of a thicker shell. A further
test (Section 4.3.4) looked at the variable of shell shape. By using shells with different shapes
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but similar SA to V ratios, we were able to produce similar release profiles for PHT. This allows
us to alter the external structure if deemed necessary for successful implantation without the
need to worry about it affecting the core drug release profile. Section 4.3.5 looked at the
effect of core drug concentration, a parameter which had not been looked at until now, but
that would allow for varying the total dosage for specific cases. Initial results suggest that an
increase in drug concentration corresponds to a slower percentage release.
This masters’ project attempted to address an issue presently seen within the epileptic
community, that of self-medication, by the development of a 3D-printed polymer implant,
doped with a combination of an anti-epileptic (Phenytoin) as well as an anti-inflammatory
(Dexamethasone); the DEX being required to negate the inflammation associated with
implantation. Not only was the printing of such an implant shown to be feasible, and perhaps
preferential to other methods in creating DDSs but a variety of internal and external
parameters were tested, demonstrating the ability to create tailored release profiles for
individual patients.

85

6. FUTURE WORK
Having successfully shown the feasibility of creating and using a dual-drug release
polymer implant, there is much room for future research. Initially, replication of results and
an increase in reproducibility is required. There is an inherent difficulty in ensuring this,
given the present state of the 3D Printing field, and specifically the field of Biofabrication.
There are, at present, no protocols or standardisation in place for bioprinters/inks and there
is no test presently available to show that a printer meets minimum requirements in order
to produce satisfactory results and to ensure reproducibility. Given that research in
Biofabrication is only in its infancy, and quite far from properly entering into industry, this is
not something that requires immediate attention, however, it will need to be addressed as
the field grows and products come to market.
Following this, a recommended study would be the (attempt at) creation of an implant
according to defined parameters e.g. shape, release profile and dosage. Our initial tests
looked at many variables, however, no attempt was made to quantify our results. Is there a
way to say, with high precision, what the effect of altering one parameter will be given
certain initial constants such as concentration, polymer type and drug? Having said this,
given the number of parameters which can be varied, there should be multiple
permutations for creating a specific release profile.
Subsequently, or perhaps concurrently, clinical assays would be necessary, in order to
test effectivity (drugs administered orally or parenterally undergo hepatic metabolism and
pass through the blood brain barrier). Of course, the introduction of surgery introduces
further complications. Although both of these drugs have already been introduced to the
market, and as such have prior TGA approval, the use of a prophylactic implant results in a
high level of danger: a toxic level of drug being implanted next to a vital organ with no quick
access to it if a problem arises. As such, strict controls must be put in place to ensure no
issues e.g. separation of the shell, would occur over a period of 12 or more months.
Contingent upon success of these trials, future research could extend to a) the testing of
other polymers and drugs b) an increase in the number of drugs. PHT was used in this initial
trial due to its availability, price, and past use in the field of epilepsy. However, it is not
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commonly used these days, and many more modern drugs have taken its place; with greater
efficacy and larger therapeutic range (see Section 1.1.4). This application is, of course, not
only relevant to epilepsy, but could be used to the prophylactic treatment of other disorders
or illnesses. The simultaneous release of multiple drugs is also of use after other forms of
surgery, wherein the outpatient is required to take a cocktail of drugs to ensure that their
body returns to full health. The use of such an implant would minimise the chance of both
overdose and relapse due to the taking of too large or small a dose. It also minimises the
chance that the patient, who often has little to no pharmacological experience, would mix
up the drug regimen, causing complications. However, the greater the number of drugs, the
higher the likelihood of their interaction with either each other or the supporting polymers,
and there are certain drugs that can only be administered through certain pathways or
require too large a dose e.g. paracetamol/acetaminophen to be able to be placed within the
implant.
Accumulation of data such as that specified above would be quite tedious and lengthy,
however, there do exist automated systems for drug release analysis which would minimise
human fatigue and error. Assuming this were successful, accumulation of enough data could
allow for the creation of an algorithm in which a specific DDS is designed according to input
preferences such as drug type, dosage, and preferred release profile.

Figure 37: Possible process for the creation and implantation of a patient specific implant
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